TR27402A - Kaplanmis, sodyum perkarbonat tanecikleri, bunlari üretmeye mahsus bir yöntem ve bunlari ihtiva eden deterjan, temizleyici ve agartici terkipleri. - Google Patents

Kaplanmis, sodyum perkarbonat tanecikleri, bunlari üretmeye mahsus bir yöntem ve bunlari ihtiva eden deterjan, temizleyici ve agartici terkipleri.

Info

Publication number: TR27402A
Authority: TR; Turkey
Prior art keywords: coated; percarbonate particles; sodium percarbonate; pct; detergent
Prior art date: 1993-04-10

Application number

TR00294/94A

Other languages

English (en)

Original Assignee

Degussa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-04-10

Filing date

1994-04-04

Publication date

1995-02-28

1994-04-04 Application filed by Degussa filed Critical Degussa

1995-02-28 Publication of TR27402A publication Critical patent/TR27402A/tr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B15/00—Peroxides; Peroxyhydrates; Peroxyacids or salts thereof; Superoxides; Ozonides
- C01B15/055—Peroxyhydrates; Peroxyacids or salts thereof
- C01B15/10—Peroxyhydrates; Peroxyacids or salts thereof containing carbon
- C01B15/106—Stabilisation of the solid compounds, subsequent to the preparation or to the crystallisation, by additives or by coating
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B15/00—Peroxides; Peroxyhydrates; Peroxyacids or salts thereof; Superoxides; Ozonides
- C01B15/055—Peroxyhydrates; Peroxyacids or salts thereof
- C01B15/10—Peroxyhydrates; Peroxyacids or salts thereof containing carbon
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D17/00—Detergent materials or soaps characterised by their shape or physical properties
- C11D17/0039—Coated compositions or coated components in the compositions, (micro)capsules
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/39—Organic or inorganic per-compounds
- C11D3/3942—Inorganic per-compounds

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Inorganic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Oil, Petroleum & Natural Gas (AREA)
Wood Science & Technology (AREA)
Detergent Compositions (AREA)

TR00294/94A 1993-04-10 1994-04-04 Kaplanmis, sodyum perkarbonat tanecikleri, bunlari üretmeye mahsus bir yöntem ve bunlari ihtiva eden deterjan, temizleyici ve agartici terkipleri. TR27402A (tr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE4311944A DE4311944A1 (de)	1993-04-10	1993-04-10	Umhüllte Natriumpercarbonatpartikel, Verfahren zu deren Herstellung und sie enthaltende Wasch-, Reinigungs- und Bleichmittelzusammensetzungen

Publications (1)

Publication Number	Publication Date
TR27402A true TR27402A (tr)	1995-02-28

Family

ID=6485306

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TR00294/94A TR27402A (tr)	1993-04-10	1994-04-04	Kaplanmis, sodyum perkarbonat tanecikleri, bunlari üretmeye mahsus bir yöntem ve bunlari ihtiva eden deterjan, temizleyici ve agartici terkipleri.

Country Status (17)

Country	Link
US (1)	US5658873A (tr)
EP (1)	EP0693039B1 (tr)
JP (1)	JP3599737B2 (tr)
KR (1)	KR100308473B1 (tr)
CN (1)	CN1120832A (tr)
AT (1)	ATE156096T1 (tr)
AU (1)	AU6207894A (tr)
CA (1)	CA2159991A1 (tr)
CZ (1)	CZ249895A3 (tr)
DE (2)	DE4311944A1 (tr)
ES (1)	ES2106515T3 (tr)
FI (1)	FI954808L (tr)
PL (1)	PL173925B1 (tr)
SI (1)	SI9400166A (tr)
TR (1)	TR27402A (tr)
TW (1)	TW265320B (tr)
WO (1)	WO1994024044A1 (tr)

Families Citing this family (606)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6335434B1 (en)	1998-06-16	2002-01-01	Isis Pharmaceuticals, Inc.,	Nucleosidic and non-nucleosidic folate conjugates
US8153602B1 (en)	1991-11-19	2012-04-10	Isis Pharmaceuticals, Inc.	Composition and methods for the pulmonary delivery of nucleic acids
AU679566B2 (en)	1993-09-03	1997-07-03	Isis Pharmaceuticals, Inc.	Amine-derivatized nucleosides and oligonucleosides
DE4439069A1 (de) *	1994-11-02	1996-05-09	Degussa	Percarbonathaltige Wasch-, Bleich- und Reinigungsmittelzusammensetzung
DE19629381A1 (de) *	1996-07-20	1998-01-22	Eilenburger Elektrolyse & Umwelttechnik Gmbh	Granulierter Aktivsauerstoffträger
US5854033A (en)	1995-11-21	1998-12-29	Yale University	Rolling circle replication reporter systems
DE19544293C2 (de) *	1995-11-28	1998-01-29	Degussa	Umhüllte Natriumpercarbonatpartikel und deren Verwendung
DE19600018A1 (de)	1996-01-03	1997-07-10	Henkel Kgaa	Waschmittel mit bestimmten oxidierten Oligosacchariden
US20030044941A1 (en)	1996-06-06	2003-03-06	Crooke Stanley T.	Human RNase III and compositions and uses thereof
US9096636B2 (en)	1996-06-06	2015-08-04	Isis Pharmaceuticals, Inc.	Chimeric oligomeric compounds and their use in gene modulation
US7812149B2 (en)	1996-06-06	2010-10-12	Isis Pharmaceuticals, Inc.	2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US5898031A (en)	1996-06-06	1999-04-27	Isis Pharmaceuticals, Inc.	Oligoribonucleotides for cleaving RNA
US6639062B2 (en)	1997-02-14	2003-10-28	Isis Pharmaceuticals, Inc.	Aminooxy-modified nucleosidic compounds and oligomeric compounds prepared therefrom
DE69834038D1 (de)	1997-07-01	2006-05-18	Isis Pharmaceutical Inc	Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre
FR2768140B1 (fr) *	1997-09-05	1999-10-08	Atochem Elf Sa	Solution sursaturee stable de perborate de sodium et son application dans la fabrication des particules de percarbonate de sodium stabilisees
US7321828B2 (en)	1998-04-13	2008-01-22	Isis Pharmaceuticals, Inc.	System of components for preparing oligonucleotides
US20040186071A1 (en)	1998-04-13	2004-09-23	Bennett C. Frank	Antisense modulation of CD40 expression
EP1080103A4 (en)	1998-05-21	2003-07-02	Isis Pharmaceuticals Inc	PREPARATIONS AND METHOD FOR THE NON-PARENTERAL ADMINISTRATION OF OLIGONUCLEOTIDES
JP2002515514A (ja)	1998-05-21	2002-05-28	アイシス・ファーマシューティカルス・インコーポレーテッド	オリゴヌクレオチドの局所送逹のための組成物及び方法
US6335439B1 (en)	1998-06-11	2002-01-01	Isis Pharmaceuticals, Inc.	Method of preparing phosphoramidites
US6867294B1 (en)	1998-07-14	2005-03-15	Isis Pharmaceuticals, Inc.	Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
US6225293B1 (en)	1998-09-02	2001-05-01	Isis Pharmaceuticals, Inc.	Methods and compounds for tracking the biodistribution of macromolecule-carrier combinations
AU9576798A (en) *	1998-09-23	2000-04-10	Procter & Gamble Company, The	Coated perborate bleach and compositions containing the same
US6077709A (en)	1998-09-29	2000-06-20	Isis Pharmaceuticals Inc.	Antisense modulation of Survivin expression
US6300320B1 (en)	1999-01-05	2001-10-09	Isis Pharmaceuticals, Inc.	Modulation of c-jun using inhibitors of protein kinase C
US7098192B2 (en)	1999-04-08	2006-08-29	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide modulation of STAT3 expression
US6656730B1 (en)	1999-06-15	2003-12-02	Isis Pharmaceuticals, Inc.	Oligonucleotides conjugated to protein-binding drugs
US6147200A (en) *	1999-08-19	2000-11-14	Isis Pharmaceuticals, Inc.	2'-O-acetamido modified monomers and oligomers
US6617442B1 (en)	1999-09-30	2003-09-09	Isis Pharmaceuticals, Inc.	Human Rnase H1 and oligonucleotide compositions thereof
US7332275B2 (en)	1999-10-13	2008-02-19	Sequenom, Inc.	Methods for detecting methylated nucleotides
US6261840B1 (en)	2000-01-18	2001-07-17	Isis Pharmaceuticals, Inc.	Antisense modulation of PTP1B expression
US20020055479A1 (en)	2000-01-18	2002-05-09	Cowsert Lex M.	Antisense modulation of PTP1B expression
EP1127840A1 (en) *	2000-02-21	2001-08-29	SOLVAY & Cie (Société Anonyme)	Process for preparing coated alkali metal percarbonate, coated alkaki metal percarbonate obtainable by this process, its use in detergent compositions, and detergent compositions containing it
AU2001253408C1 (en) *	2000-04-13	2008-12-04	Mervyn Merrilees	Therapeutic compounds and methods for formulating V3, A Versican Isoform
KR100366556B1 (ko)	2000-04-26	2003-01-09	동양화학공업주식회사	세제용 입상 코티드 과탄산나트륨과 이의 제조방법
US6680172B1 (en)	2000-05-16	2004-01-20	Regents Of The University Of Michigan	Treatments and markers for cancers of the central nervous system
US6958214B2 (en)	2000-07-10	2005-10-25	Sequenom, Inc.	Polymorphic kinase anchor proteins and nucleic acids encoding the same
US8568766B2 (en)	2000-08-24	2013-10-29	Gattadahalli M. Anantharamaiah	Peptides and peptide mimetics to treat pathologies associated with eye disease
EP1326892A2 (en)	2000-10-12	2003-07-16	University of Rochester	Compositions that inhibit proliferation of cancer cells
US7767802B2 (en)	2001-01-09	2010-08-03	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of anti-apoptotic genes
US6573051B2 (en) *	2001-03-09	2003-06-03	Molecular Staging, Inc.	Open circle probes with intramolecular stem structures
AU2002257067A1 (en)	2001-03-14	2002-09-24	Myriad Genetics, Inc	Tsg101-gag interaction and use thereof
US7803915B2 (en)	2001-06-20	2010-09-28	Genentech, Inc.	Antibody compositions for the diagnosis and treatment of tumor
CA2633171C (en)	2001-06-20	2012-11-20	Genentech, Inc.	Antibodies against tumor-associated antigenic target (tat) polypeptides
CA2790034A1 (en)	2001-06-21	2003-01-03	Isis Pharmaceuticals, Inc.	Antisense modulation of superoxide dismutase 1, soluble expression
US6964950B2 (en)	2001-07-25	2005-11-15	Isis Pharmaceuticals, Inc.	Antisense modulation of C-reactive protein expression
US7425545B2 (en)	2001-07-25	2008-09-16	Isis Pharmaceuticals, Inc.	Modulation of C-reactive protein expression
US20030096772A1 (en)	2001-07-30	2003-05-22	Crooke Rosanne M.	Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
US7407943B2 (en)	2001-08-01	2008-08-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein B expression
US7227014B2 (en)	2001-08-07	2007-06-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein (a) expression
EP1487877B1 (en)	2001-09-18	2010-10-27	Genentech, Inc.	Compositions and methods for the diagnosis of tumors
NZ585001A (en)	2001-10-09	2011-08-26	Isis Pharmaceuticals Inc	Antisense modulation of insulin-like growth factor binding protein 5 expression
US6750019B2 (en)	2001-10-09	2004-06-15	Isis Pharmaceuticals, Inc.	Antisense modulation of insulin-like growth factor binding protein 5 expression
WO2003088808A2 (en)	2002-04-16	2003-10-30	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
US20030170678A1 (en) *	2001-10-25	2003-09-11	Neurogenetics, Inc.	Genetic markers for Alzheimer's disease and methods using the same
US6965025B2 (en)	2001-12-10	2005-11-15	Isis Pharmaceuticals, Inc.	Antisense modulation of connective tissue growth factor expression
NZ533933A (en)	2002-01-02	2008-06-30	Genentech Inc	Compositions and methods for the diagnosis and treatment of glioma tumor
US7553619B2 (en)	2002-02-08	2009-06-30	Qiagen Gmbh	Detection method using dissociated rolling circle amplification
US7169916B2 (en) *	2002-04-01	2007-01-30	Isis Pharmaceuticals, Inc.	Chloral-free DCA in oligonucleotide synthesis
AU2003228809A1 (en)	2002-05-03	2003-11-17	Sequenom, Inc.	Kinase anchor protein muteins, peptides thereof, and related methods
US7199107B2 (en)	2002-05-23	2007-04-03	Isis Pharmaceuticals, Inc.	Antisense modulation of kinesin-like 1 expression
AU2003276131A1 (en) *	2002-06-18	2003-12-31	Epigenesis Pharmaceuticals, Inc.	A dry powder oligonucleotide formulation, preparation and its uses
AU2003257181A1 (en)	2002-08-05	2004-02-23	University Of Rochester	Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof
EP2330194A3 (en)	2002-09-13	2011-10-12	Replicor, Inc.	Non-sequence complementary antiviral oligonucleotides
JP2006500030A (ja) *	2002-09-20	2006-01-05	イェールユニバーシティ	リボスイッチ、その使用方法、ならびにリボスイッチとともに用いるための組成物
US7229976B2 (en)	2002-09-26	2007-06-12	Isis Pharmaceuticals, Inc.	Modulation of forkhead box O1A expression
US9150605B2 (en) *	2002-11-05	2015-10-06	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
US8604183B2 (en)	2002-11-05	2013-12-10	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
US9150606B2 (en)	2002-11-05	2015-10-06	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
AU2003287505A1 (en)	2002-11-05	2004-06-03	Isis Pharmaceuticals, Inc.	Chimeric oligomeric compounds and their use in gene modulation
EP2336318B1 (en)	2002-11-13	2013-04-24	Genzyme Corporation	Antisense modulation of apolipoprotein b expression
SI1569695T1 (sl)	2002-11-13	2013-08-30	Genzyme Corporation	Protismiselna modulacija ekspresije apolipoproteina B
EP2292259A3 (en)	2002-11-15	2011-03-23	MUSC Foundation For Research Development	Complement receptor 2 targeted complement modulators
CA2506127C (en)	2002-11-15	2013-07-09	Morphotek, Inc.	Methods of generating high-production of antibodies from hybridomas created by in vitro immunization
US7557092B2 (en)	2002-11-21	2009-07-07	University Of Utah Research Foundation	Purinergic modulation of smell
US7144999B2 (en)	2002-11-23	2006-12-05	Isis Pharmaceuticals, Inc.	Modulation of hypoxia-inducible factor 1 alpha expression
US20040121338A1 (en) *	2002-12-19	2004-06-24	Alsmadi Osama A.	Real-time detection of rolling circle amplification products
JP4886298B2 (ja)	2002-12-20	2012-02-29	キアゲンゲゼルシャフトミットベシュレンクテルハフツング	核酸増幅
US9487823B2 (en)	2002-12-20	2016-11-08	Qiagen Gmbh	Nucleic acid amplification
DE10320197A1 (de) *	2002-12-20	2004-07-08	Degussa Ag	Umhüllte Persauerstoffverbindungen mit kontrollierter Freisetzung, Verfahren zu ihrer Herstellung und ihrer Verwendung
US6977153B2 (en)	2002-12-31	2005-12-20	Qiagen Gmbh	Rolling circle amplification of RNA
WO2004072284A1 (en)	2003-02-11	2004-08-26	Antisense Therapeutics Ltd	Modulation of insulin like growth factor i receptor expression
US7002006B2 (en) *	2003-02-12	2006-02-21	Isis Pharmaceuticals, Inc.	Protection of nucleosides
US7803781B2 (en)	2003-02-28	2010-09-28	Isis Pharmaceuticals, Inc.	Modulation of growth hormone receptor expression and insulin-like growth factor expression
US20040185559A1 (en)	2003-03-21	2004-09-23	Isis Pharmaceuticals Inc.	Modulation of diacylglycerol acyltransferase 1 expression
US8043834B2 (en)	2003-03-31	2011-10-25	Qiagen Gmbh	Universal reagents for rolling circle amplification and methods of use
US7598227B2 (en)	2003-04-16	2009-10-06	Isis Pharmaceuticals Inc.	Modulation of apolipoprotein C-III expression
US7399853B2 (en)	2003-04-28	2008-07-15	Isis Pharmaceuticals	Modulation of glucagon receptor expression
EP1660512A4 (en)	2003-06-02	2009-12-23	Isis Pharmaceuticals Inc	SYNTHESIS OF OLIGONUCLEOTIDES USING ALTERNATIVE SOLVENTS
BRPI0410886A (pt)	2003-06-03	2006-07-04	Isis Pharmaceuticals Inc	composto de filamento duplo, composição farmacêutica, sal farmaceuticamente aceitável, métodos de modificação do ácido nucleico que codifica a survivina humana, de inibição da expressão da suvivina em células ou tecidos, e de tratamento de uma condição associada com a expressão ou superexpressão da suvivina, e, oligonucleotìdeo de rnai de filamento único
AU2004263830B2 (en)	2003-06-13	2008-12-18	Alnylam Pharmaceuticals, Inc.	Double-stranded ribonucleic acid with increased effectiveness in an organism
EP1644475A4 (en)	2003-06-20	2009-06-03	Isis Pharmaceuticals Inc	DOUBLE-STRAND COMPOSITIONS WITH A 3'-ENDO-MODIFIED STRING FOR USE IN GENE MODULATION
US7683036B2 (en)	2003-07-31	2010-03-23	Regulus Therapeutics Inc.	Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
US7825235B2 (en)	2003-08-18	2010-11-02	Isis Pharmaceuticals, Inc.	Modulation of diacylglycerol acyltransferase 2 expression
US20050053981A1 (en)	2003-09-09	2005-03-10	Swayze Eric E.	Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
WO2005027962A1 (en)	2003-09-18	2005-03-31	Isis Pharmaceuticals, Inc.	4’-thionucleosides and oligomeric compounds
KR100750788B1 (ko)	2003-09-18	2007-08-20	아이시스 파마수티컬즈 인코포레이티드	ｅＩＦ4Ｅ 발현의 조정
US20050191653A1 (en)	2003-11-03	2005-09-01	Freier Susan M.	Modulation of SGLT2 expression
SI2295073T1 (sl)	2003-11-17	2014-07-31	Genentech, Inc.	Protitelo proti CD22 za zdravljenje tumorja hematopoetskega izvora
US20050164271A1 (en)	2004-01-20	2005-07-28	Sanjay Bhanot	Modulation of glucocorticoid receptor expression
US7468431B2 (en)	2004-01-22	2008-12-23	Isis Pharmaceuticals, Inc.	Modulation of eIF4E-BP2 expression
US8778900B2 (en) *	2004-01-22	2014-07-15	Isis Pharmaceuticals, Inc.	Modulation of eIF4E-BP1 expression
US8569474B2 (en)	2004-03-09	2013-10-29	Isis Pharmaceuticals, Inc.	Double stranded constructs comprising one or more short strands hybridized to a longer strand
WO2005089268A2 (en)	2004-03-15	2005-09-29	Isis Pharmaceuticals, Inc.	Compositions and methods for optimizing cleavage of rna by rnase h
WO2005097817A2 (en)	2004-04-05	2005-10-20	Alnylam Pharmaceuticals, Inc.	Process and reagents for oligonucleotide synthesis and purification
US20050244869A1 (en)	2004-04-05	2005-11-03	Brown-Driver Vickie L	Modulation of transthyretin expression
US7674778B2 (en)	2004-04-30	2010-03-09	Alnylam Pharmaceuticals	Oligonucleotides comprising a conjugate group linked through a C5-modified pyrimidine
EP3225633B1 (en)	2004-05-21	2020-03-25	The UAB Research Foundation	Variable lymphocyte receptors, related polypeptides and nucleic acids, and uses thereof
US8394947B2 (en)	2004-06-03	2013-03-12	Isis Pharmaceuticals, Inc.	Positionally modified siRNA constructs
WO2006023880A2 (en) *	2004-08-23	2006-03-02	Isis Pharmaceuticals, Inc.	Compounds and methods for the characterization of oligonucleotides
US7884086B2 (en)	2004-09-08	2011-02-08	Isis Pharmaceuticals, Inc.	Conjugates for use in hepatocyte free uptake assays
ES2729826T3 (es)	2004-09-23	2019-11-06	Arc Medical Devices Inc	Composiciones farmacéuticas y métodos relacionados para inhibir adherencias fibrosas o enfermedad inflamatoria usando fucanos con bajo contenido de sulfato
AU2005327506B2 (en)	2004-10-20	2010-07-08	Antisense Therapeutics Ltd	Antisense modulation of integrin alpha4 expression
US20060105937A1 (en) *	2004-11-15	2006-05-18	Melani Hardt Duran	Aqueous cleaning composition
WO2006063031A2 (en)	2004-12-06	2006-06-15	Haplomics	Allelic variants of human factor viii
EP1869076A2 (en)	2005-03-10	2007-12-26	Genentech, Inc.	Methods and compositions for modulating vascular integrity
US7476733B2 (en)	2005-03-25	2009-01-13	The United States Of America As Represented By The Department Of Health And Human Services	Development of a real-time PCR assay for detection of pneumococcal DNA and diagnosis of pneumococccal disease
US8309303B2 (en)	2005-04-01	2012-11-13	Qiagen Gmbh	Reverse transcription and amplification of RNA with simultaneous degradation of DNA
GB0508622D0 (en) *	2005-04-28	2005-06-08	Probe Ind Ltd	Method for treating effluent
EP1891141B1 (en)	2005-05-31	2016-11-16	Ecole Polytechnique Fédérale de Lausanne (EPFL)	Triblock copolymers for cytoplasmic delivery of gene-based drugs
WO2006133022A2 (en)	2005-06-03	2006-12-14	The Johns Hopkins University	Compositions and methods for decreasing microrna expression for the treatment of neoplasia
WO2006138145A1 (en)	2005-06-14	2006-12-28	Northwestern University	Nucleic acid functionalized nanoparticles for therapeutic applications
CA2618665C (en)	2005-08-11	2012-11-13	J. Craig Venter Institute	Method for in vitro recombination
CA2617693A1 (en)	2005-08-17	2007-02-22	Medexis S.A.	Composition and method for determination of ck19 expression
CA2620856C (en)	2005-08-29	2017-11-28	Isis Pharmaceuticals, Inc.	Methods for use in modulating mir-122a
WO2007027894A2 (en)	2005-08-29	2007-03-08	Isis Pharmaceuticals, Inc.	Antisense compounds having enhanced anti-microrna activity
EP1762627A1 (de)	2005-09-09	2007-03-14	Qiagen GmbH	Verfahren zur Aktivierung einer Nukleinsäure für eine Polymerase-Reaktion
US8080534B2 (en)	2005-10-14	2011-12-20	Phigenix, Inc	Targeting PAX2 for the treatment of breast cancer
EP2392647A1 (en)	2005-10-14	2011-12-07	MUSC Foundation For Research Development	Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy
WO2007051045A2 (en)	2005-10-28	2007-05-03	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of huntingtin gene
EP1942948A4 (en) *	2005-11-04	2010-03-03	Alnylam Pharmaceuticals Inc	COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF THE NAV1.8 GENE
CA2626690A1 (en)	2005-11-09	2007-05-18	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of factor v leiden mutant gene
CA2630602A1 (en)	2005-11-21	2007-05-31	Isis Pharmaceuticals, Inc.	Modulation of eif4e-bp2 expression
JP2009524411A (ja) *	2005-12-21	2009-07-02	イェールユニバーシティー	リボスイッチの調節に関連した方法および組成物
US8288354B2 (en)	2005-12-28	2012-10-16	The Scripps Research Institute	Natural antisense and non-coding RNA transcripts as drug targets
PT2161038E (pt)	2006-01-26	2014-03-10	Isis Pharmaceuticals Inc	Composições e suas utilizações dirigidas à huntingtina
US7569686B1 (en)	2006-01-27	2009-08-04	Isis Pharmaceuticals, Inc.	Compounds and methods for synthesis of bicyclic nucleic acid analogs
JP5342881B2 (ja)	2006-01-27	2013-11-13	アイシスファーマシューティカルズ，インコーポレーテッド	６−修飾された二環式核酸類似体
EP1984499B1 (en)	2006-01-27	2015-05-27	Isis Pharmaceuticals, Inc.	Oligomeric compounds and compositions for the use in modulation of micrornas
US7718629B2 (en)	2006-03-31	2010-05-18	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of Eg5 gene
EP2013344B1 (en)	2006-05-03	2012-08-29	Baltic Technology Development, Ltd.	Antisense agents combining strongly bound base - modified oligonucleotide and artificial nuclease
EP2023940B1 (en)	2006-05-05	2011-06-22	Isis Pharmaceuticals, Inc.	Compounds and methods for modulating expression of sglt2
EP2505649A1 (en)	2006-05-05	2012-10-03	Isis Pharmaceuticals, Inc.	Compounds and methods for modulating expression of GCGR
AU2007249349B2 (en) *	2006-05-11	2012-03-08	Isis Pharmaceuticals, Inc.	5'-Modified bicyclic nucleic acid analogs
US7666854B2 (en) *	2006-05-11	2010-02-23	Isis Pharmaceuticals, Inc.	Bis-modified bicyclic nucleic acid analogs
EP2392583A1 (en)	2006-05-19	2011-12-07	Alnylam Europe AG.	RNAi modulation of Aha and therapeutic uses thereof
EP2584051B1 (en)	2006-05-22	2014-07-16	Alnylam Pharmaceuticals Inc.	Compositions and methods for inhibiting expressions of IKK-B gene
US8198253B2 (en)	2006-07-19	2012-06-12	Isis Pharmaceuticals, Inc.	Compositions and their uses directed to HBXIP
US8101585B2 (en) *	2006-08-04	2012-01-24	Isis Pharmaceuticals, Inc.	Compositions and methods for the modulation of JNK proteins
EP2061799A4 (en) *	2006-09-11	2010-12-22	Univ Yale	METHOD AND COMPOSITIONS FOR USE OF LYSIN RIBOSWITCHES
JP5560039B2 (ja)	2006-10-05	2014-07-23	マサチューセッツインスティテュートオブテクノロジー	ハイスループット分析のための多機能のコード化された粒子
WO2008049085A1 (en)	2006-10-18	2008-04-24	Isis Pharmaceuticals, Inc.	Antisense compounds
US8999317B2 (en)	2006-11-01	2015-04-07	University Of Rochester	Methods and compositions related to the structure and function of APOBEC3G
JP2010510807A (ja) *	2006-11-27	2010-04-08	アイシスファーマシューティカルズ，インコーポレーテッド	高コレステロール血症を治療するための方法
US8093222B2 (en)	2006-11-27	2012-01-10	Isis Pharmaceuticals, Inc.	Methods for treating hypercholesterolemia
KR20090089462A (ko)	2006-12-11	2009-08-21	유니버시티 오브 유타 리써치 파운데이션	병적 혈관형성 및 혈관 투과성을 치료하기 위한 조성물 및 방법
US20100129358A1 (en)	2006-12-22	2010-05-27	University Of Utah Research Foundation	Method of detecting ocular diseases and pathologic conditions and treatment of same
US8507200B2 (en)	2007-02-09	2013-08-13	Northwestern University	Particles for detecting intracellular targets
WO2008127789A2 (en) *	2007-02-27	2008-10-23	Northwestern University	Molecule attachment to nanoparticles
CA2681634A1 (en)	2007-03-22	2008-09-25	Yale University	Methods and compositions related to riboswitches that control alternative splicing
AU2008232891B2 (en)	2007-03-29	2012-01-12	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of a gene from the Ebola
EP2639315A1 (en)	2007-05-11	2013-09-18	The Johns Hopkins University	Biomarkers for melanoma
SG174103A1 (en)	2007-05-29	2011-09-29	Univ Yale	Riboswitches and methods and compositions for use of and with riboswitches
EP2164994A4 (en) *	2007-05-29	2010-07-21	Univ Yale Inc	METHODS AND COMPOSITIONS RELATED TO RIBOINTERRUPTERS THAT REGULATE ALTERNATIVE SPLICE AND RNA PROCESSING
DK2160464T3 (da)	2007-05-30	2014-08-04	Univ Northwestern	Nukleinsyrefunktionaliserede nanopartikler til terapeutiske anvendelser
EP2170917B1 (en)	2007-05-30	2012-06-27	Isis Pharmaceuticals, Inc.	N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
US7807372B2 (en) *	2007-06-04	2010-10-05	Northwestern University	Screening sequence selectivity of oligonucleotide-binding molecules using nanoparticle based colorimetric assay
EP2173760B2 (en)	2007-06-08	2015-11-04	Isis Pharmaceuticals, Inc.	Carbocyclic bicyclic nucleic acid analogs
CA2692579C (en) *	2007-07-05	2016-05-03	Isis Pharmaceuticals, Inc.	6-disubstituted bicyclic nucleic acid analogs
WO2009023855A2 (en)	2007-08-15	2009-02-19	Isis Pharmaceuticals, Inc.	Tetrahydropyran nucleic acid analogs
AU2008296478B9 (en)	2007-08-28	2015-03-19	The Uab Research Foundation	Synthetic apolipoprotein E mimicking polypeptides and methods of use
US8557767B2 (en)	2007-08-28	2013-10-15	Uab Research Foundation	Synthetic apolipoprotein E mimicking polypeptides and methods of use
US8445217B2 (en)	2007-09-20	2013-05-21	Vanderbilt University	Free solution measurement of molecular interactions by backscattering interferometry
US7951785B2 (en)	2007-09-21	2011-05-31	California Institute Of Technology	NFIA in glial fate determination, glioma therapy and astrocytoma treatment
US8916531B2 (en)	2007-11-20	2014-12-23	Isis Pharmaceuticals, Inc.	Modulation of CD40 expression
EP2848688A1 (en)	2007-12-10	2015-03-18	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of factor VII gene
WO2009086558A1 (en)	2008-01-02	2009-07-09	Tekmira Pharmaceuticals Corporation	Improved compositions and methods for the delivery of nucleic acids
SG188121A1 (en)	2008-03-05	2013-03-28	Alnylam Pharmaceuticals Inc	Compositions and methods for inhibiting expression of eg5 and vegf genes
US8846639B2 (en) *	2008-04-04	2014-09-30	Isis Pharmaceutical, Inc.	Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
DK2285819T3 (da) *	2008-04-04	2013-12-02	Isis Pharmaceuticals Inc	Oligomere forbindelser omfattende neutralt bundne, terminale bicykliske nukleosider
AU2009237577B2 (en)	2008-04-18	2014-06-05	Baxter Healthcare Sa	Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
CN101270232B (zh) *	2008-04-22	2011-04-20	浙江时代金科过氧化物有限公司	一种颗粒型包膜过碳酸钠的制备方法
EP2280995A2 (en) *	2008-04-29	2011-02-09	Wyeth LLC	Methods for treating inflammation
CA2726052A1 (en)	2008-06-04	2009-12-10	The Board Of Regents Of The University Of Texas System	Modulation of gene expression through endogenous small rna targeting of gene promoters
WO2010014592A1 (en)	2008-07-29	2010-02-04	The Board Of Regents Of The University Of Texas Sytem	Selective inhibition of polyglutamine protein expression
EP3375451A1 (en)	2008-08-25	2018-09-19	Excaliard Pharmaceuticals, Inc.	Method for reducing scarring during wound healing using antisense compounds directed to ctgf
NZ601660A (en)	2008-08-25	2014-05-30	Excaliard Pharmaceuticals Inc	Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
EP3208337A1 (en)	2008-09-02	2017-08-23	Alnylam Pharmaceuticals, Inc.	Compositions for combined inhibition of mutant egfr and il-6 expression
WO2010036698A1 (en) *	2008-09-24	2010-04-01	Isis Pharmaceuticals, Inc.	Substituted alpha-l-bicyclic nucleosides
US20100075883A1 (en) *	2008-09-24	2010-03-25	Ecolab Inc.	Granular cleaning and disinfecting composition
CA2739170A1 (en)	2008-09-25	2010-04-01	Alnylam Pharmaceuticals, Inc.	Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene
CN104119242B (zh)	2008-10-09	2017-07-07	泰米拉制药公司	改善的氨基脂质和递送核酸的方法
EA036772B1 (ru)	2008-10-20	2020-12-18	Элнилэм Фармасьютикалз, Инк.	Композиции и способы для ингибирования экспрессии транстиретина
EP2358398A2 (en)	2008-10-24	2011-08-24	Isis Pharmaceuticals, Inc.	Oligomeric compounds and methods
CN106955360A (zh)	2008-11-24	2017-07-18	西北大学	多价rna纳米颗粒组合物
EP2370580B1 (en)	2008-12-04	2019-09-11	CuRNA, Inc.	Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1
CN102361985B (zh)	2008-12-04	2017-06-20	库尔纳公司	通过抑制肿瘤抑制基因的天然反义转录物治疗肿瘤抑制基因相关性疾病
RU2620970C2 (ru)	2008-12-04	2017-05-30	КьюРНА,Инк.,	Лечение связанных с эритропоэтином (еро) заболеваний путем ингибирования природного антисмыслового транскрипта к еро
EP2373382B1 (en)	2008-12-10	2017-02-15	Alnylam Pharmaceuticals, Inc.	Gnaq targeted dsrna compositions and methods for inhibiting expression
US20100233270A1 (en)	2009-01-08	2010-09-16	Northwestern University	Delivery of Oligonucleotide-Functionalized Nanoparticles
KR101546673B1 (ko) *	2009-01-15	2015-08-25	삼성전자주식회사	전자 사진용 토너 및 그의 제조방법
EP3243504A1 (en)	2009-01-29	2017-11-15	Arbutus Biopharma Corporation	Improved lipid formulation
US8536320B2 (en)	2009-02-06	2013-09-17	Isis Pharmaceuticals, Inc.	Tetrahydropyran nucleic acid analogs
US20120021515A1 (en)	2009-02-06	2012-01-26	Swayze Eric E	Oligomeric compounds and methods
WO2010093904A2 (en)	2009-02-12	2010-08-19	Curna, Inc.	Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
KR101805199B1 (ko)	2009-02-12	2017-12-05	큐알엔에이, 인크.	신경교세포 유래된 신경영양성 인자 (ｇｄｎｆ)에 대한 자연 안티센스 전사체의 저해에 의한 신경교세포 유래된 신경영양성 인자 (ｇｄｎｆ) 관련된 질환의 치료
WO2010099341A1 (en)	2009-02-26	2010-09-02	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of mig-12 gene
EP2403946A4 (en)	2009-03-04	2012-11-14		TREATMENT OF SIRTUIN 1 (SIRT1) -HANDLED ILLNESSES BY INHIBITING THE NATURAL ANTISENSE TRANSCRIPT AGAINST SIRT 1
AU2010223967B2 (en)	2009-03-12	2015-07-30	Alnylam Pharmaceuticals, Inc.	Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
EP2408919B1 (en)	2009-03-16	2017-10-18	CuRNA, Inc.	Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2
CA2755404C (en)	2009-03-17	2020-03-24	Curna, Inc.	Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
EP2419535B1 (en)	2009-04-15	2022-08-17	Northwestern University	Delivery of oligonucleotide-functionalized nanoparticles
EP3248618A1 (en)	2009-04-22	2017-11-29	Massachusetts Institute Of Technology	Innate immune suppression enables repeated delivery of long rna molecules
EP2421972A2 (en)	2009-04-24	2012-02-29	The Board of Regents of The University of Texas System	Modulation of gene expression using oligomers that target gene regions downstream of 3' untranslated regions
CA2760589C (en)	2009-05-01	2019-08-20	Joseph Collard	Treatment of hemoglobin (hbf/hbg) related diseases by inhibition of natural antisense transcript to hbf/hbg
KR20180094137A (ko)	2009-05-05	2018-08-22	알닐람 파마슈티칼스 인코포레이티드	지질 조성물
JP5889783B2 (ja)	2009-05-05	2016-03-22	テクミラファーマシューティカルズコーポレイションＴｅｋｍｉｒａＰｈａｒｍａｃｅｕｔｉｃａｌｓＣｏｒｐｏｒａｔｉｏｎ	免疫細胞へオリゴヌクレオチドを送達する方法
CN102459596B (zh)	2009-05-06	2016-09-07	库尔纳公司	通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
KR101722541B1 (ko)	2009-05-06	2017-04-04	큐알엔에이, 인크.	Ｔｔｐ에 대한 천연 안티센스 전사체의 억제에 의한 트리스테트라프롤린 관련된 질환의 치료
US20120107331A1 (en)	2009-05-15	2012-05-03	Yale University	Gemm riboswitches, structure-based compound design with gemm riboswitches, and methods and compositions for use of and with gemm riboswitches
WO2010135329A2 (en)	2009-05-18	2010-11-25	Curna, Inc.	Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
CA2762987A1 (en)	2009-05-22	2010-11-25	Joseph Collard	Treatment of transcription factor e3 (tfe3) and insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to tfe3
KR101704988B1 (ko)	2009-05-28	2017-02-08	큐알엔에이, 인크.	항바이러스 유전자에 대한 천연 안티센스 전사체의 억제에 의한 항바이러스 유전자 관련된 질환의 치료
MX342785B (es)	2009-06-10	2016-10-12	Alnylam Pharmaceuticals Inc	Formulacion mejorada de lipido.
CA2765700C (en)	2009-06-16	2021-01-05	Opko Curna, Llc	Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
ES2629339T3 (es)	2009-06-16	2017-08-08	Curna, Inc.	Tratamiento de enfermedades relacionadas con la paraoxonasa 1 (pon1) por inhibición de transcrito antisentido natural a pon1
PT3305302T (pt)	2009-06-17	2018-12-14	Biogen Ma Inc	Composições e métodos de modulação de excisões de smn2 em um sujeito
ES2618894T3 (es)	2009-06-24	2017-06-22	Curna, Inc.	Tratamiento de enfermedades relacionadas con el receptor del factor de necrosis tumoral 2 (tnfr2) por inhibición del transcrito natural antisentido para tnfr2
CN102482672B (zh)	2009-06-26	2016-11-09	库尔纳公司	通过抑制唐氏综合征基因的天然反义转录物治疗唐氏综合征基因相关疾病
ES2585360T3 (es)	2009-08-05	2016-10-05	Curna, Inc.	Tratamiento de enfermedades relacionadas con un gen de la insulina (INS) por inhibición de la transcripción antisentido natural en un gen de la insulina (INS)
US9029338B2 (en)	2009-08-14	2015-05-12	Alnylam Pharmaceuticals, Inc.	Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
WO2011022420A1 (en)	2009-08-17	2011-02-24	Yale University	Methylation biomarkers and methods of use
EP2470657B1 (en)	2009-08-25	2019-10-23	CuRNA, Inc.	Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
DK2473522T3 (en)	2009-09-02	2016-11-28	Genentech Inc	Smoothened MUTANT AND METHODS OF USING THE SAME
US8697386B2 (en)	2009-10-22	2014-04-15	Genentech, Inc.	Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
CA2778532A1 (en)	2009-10-27	2011-05-12	Swift Biosciences, Inc.	Polynucleotide primers and probes
DK2494075T3 (en)	2009-10-30	2018-07-23	Univ Northwestern	TABLE-MANAGED NANOCONJUGATES
US20110110860A1 (en)	2009-11-02	2011-05-12	The Board Of Regents Of The University Of Texas System	Modulation of ldl receptor gene expression with double-stranded rnas targeting the ldl receptor gene promoter
KR20120102674A (ko)	2009-11-03	2012-09-18	유니버시티 오브 버지니아 페이턴트 파운데이션	중합체 분석물을 검출하는 다용도의 가시적인 방법
EP2504450B1 (en)	2009-11-23	2016-07-06	Swift Biosciences, Inc.	Devices to extend single stranded target molecules
BR112012012750A2 (pt)	2009-11-30	2020-08-11	Genentech Inc	anticorpo isolado, célula, ácido nucleíco isolado e método
CA2782366A1 (en)	2009-12-16	2011-07-14	Opko Curna, Llc	Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1
RU2619185C2 (ru)	2009-12-23	2017-05-12	Курна, Инк.	Лечение заболеваний, связанных с разобщающим белком 2 (ucp2), путем ингибирования природного антисмыслового транскрипта к ucp2
NO2516648T3 (tr)	2009-12-23	2018-04-07
US8921334B2 (en)	2009-12-29	2014-12-30	Curna, Inc.	Treatment of nuclear respiratory factor 1 (NRF1) related diseases by inhibition of natural antisense transcript to NRF1
US8962585B2 (en)	2009-12-29	2015-02-24	Curna, Inc.	Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63
DK2521784T3 (en)	2010-01-04	2018-03-12	Curna Inc	TREATMENT OF INTERFERON REGULATORY FACTOR 8- (IRF8) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPT TO IRF8
KR101853509B1 (ko)	2010-01-06	2018-04-30	큐알엔에이, 인크.	췌장 발달 유전자에 대한 천연 안티센스 전사체의 억제에 의한 췌장 발달 유전자와 관련된 질환의 치료
KR101854926B1 (ko)	2010-01-11	2018-05-04	큐알엔에이, 인크.	성 호르몬 결합 글로불린 (ｓｈｂｇ)에 대한 자연 안티센스 전사체의 저해에 의한 성 호르몬 결합 글로불린 (ｓｈｂｇ) 관련된 질환의 치료
SG182365A1 (en)	2010-01-12	2012-08-30	Univ Yale	Structured rna motifs and compounds and methods for their use
US20110177107A1 (en) *	2010-01-14	2011-07-21	Haplomics, Inc.	Predicting and reducing alloimmunogenicity of protein therapeutics
DK2529015T3 (en)	2010-01-25	2018-02-26	Curna Inc	TREATMENT OF RNASE H1-RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO RNASE H1
WO2011097388A1 (en)	2010-02-03	2011-08-11	Alnylam Pharmaceuticals, Inc.	Selective inhibition of polyglutamine protein expression
WO2011097407A1 (en)	2010-02-04	2011-08-11	Ico Therapeutics Inc.	Dosing regimens for treating and preventing ocular disorders using c-raf antisense
RU2608496C2 (ru)	2010-02-22	2017-01-18	Курна, Инк.	Лечение заболеваний, связанных с пирролин-5 карбоксилатредуктазой 1(pycr1), путем ингибирования природного антисмыслового транскрипта к pycr1
TWI429453B (zh)	2010-02-23	2014-03-11	建南德克公司	抗tat419抗體及其用途
WO2011105902A2 (en)	2010-02-23	2011-09-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Antagonists of complement component 8-beta (c8-beta) and uses thereof
WO2011105901A2 (en)	2010-02-23	2011-09-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Antagonists of complement component 9 (c9) and uses thereof
WO2011105900A2 (en)	2010-02-23	2011-09-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
WO2011112516A1 (en)	2010-03-08	2011-09-15	Ico Therapeutics Inc.	Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides
US20130101512A1 (en)	2010-03-12	2013-04-25	Chad A. Mirkin	Crosslinked polynucleotide structure
EP3329924B1 (en)	2010-03-29	2021-05-05	Alnylam Pharmaceuticals, Inc.	Dsrna therapy for transthyretin (ttr) related ocular amyloidosis
CA2792561C (en)	2010-04-06	2021-10-26	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of cd274/pd-l1 gene
KR101900962B1 (ko)	2010-04-09	2018-09-20	큐알엔에이, 인크.	섬유아세포 성장 인자 21 (ｆｇｆ21)에 대한 자연 안티센스 전사체의 저해에 의한 섬유아세포 성장 인자 21 (ｆｇｆ21) 관련된 질환의 치료
WO2011133695A2 (en)	2010-04-20	2011-10-27	Swift Biosciences, Inc.	Materials and methods for nucleic acid fractionation by solid phase entrapment and enzyme-mediated detachment
RS56011B1 (sr)	2010-04-29	2017-09-29	Ionis Pharmaceuticals Inc	Modulacija ekspresije transtiretina
RU2018110642A (ru)	2010-05-03	2019-02-27	Курна, Инк.	Лечение заболеваний, связанных с сиртуином (sirt), путем ингибирования природного антисмыслового транскрипта к сиртуину (sirt)
MX342239B (es)	2010-05-03	2016-09-21	Genentech Inc *	Composiciones y metodos para el diagnostico y tratamiento de tumores.
TWI586356B (zh)	2010-05-14	2017-06-11	可娜公司	藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
WO2011150226A1 (en)	2010-05-26	2011-12-01	Landers James P	Method for detecting nucleic acids based on aggregate formation
CA2799207C (en)	2010-05-26	2019-03-26	Curna, Inc.	Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
CA2801066C (en)	2010-06-02	2021-02-09	Alnylam Pharmaceuticals, Inc.	Compositions and methods directed to treating liver fibrosis
EP2576839B1 (en)	2010-06-07	2017-05-10	Firefly Bioworks, Inc.	Nucleic acid detection and quantification by post-hybridization labeling and universal encoding
US9638632B2 (en)	2010-06-11	2017-05-02	Vanderbilt University	Multiplexed interferometric detection system and method
US9168297B2 (en)	2010-06-23	2015-10-27	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Regulation of skin pigmentation by neuregulin-1 (NRG-1)
CN103068982B (zh)	2010-07-14	2017-06-09	库尔纳公司	通过抑制盘状大同系物(dlg)的天然反义转录物而治疗dlg相关疾病
WO2012021554A1 (en)	2010-08-09	2012-02-16	Yale University	Cyclic di-gmp-ii riboswitches, motifs, and compounds, and methods for their use
US8481680B2 (en)	2010-10-05	2013-07-09	Genentech, Inc.	Mutant smoothened and methods of using the same
ES2640755T3 (es)	2010-10-06	2017-11-06	Curna, Inc.	Tratamiento de enfermedades relacionadas con la Sialidasa 4 (neu4) mediante inhibición del transcrito antisentido natural al gen neu4
US9222088B2 (en)	2010-10-22	2015-12-29	Curna, Inc.	Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA
ES2677070T3 (es)	2010-10-27	2018-07-27	Curna, Inc.	Tratamiento de enfermedades relacionadas con el regulador del desarrollo 1 asociado a interferón (ifrd1) mediante inhibición del transcrito antisentido natural al gen ifrd1
US9339513B2 (en)	2010-11-09	2016-05-17	Alnylam Pharmaceuticals, Inc.	Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
ES2657590T3 (es)	2010-11-23	2018-03-06	Curna, Inc.	Tratamiento de enfermedades relacionadas con nanog mediante inhibición del transcrito antisentido natural a nanog
US9150926B2 (en)	2010-12-06	2015-10-06	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Diagnosis and treatment of adrenocortical tumors using human microRNA-483
EP2648763A4 (en)	2010-12-10	2014-05-14	Alnylam Pharmaceuticals Inc	COMPOSITIONS AND METHODS FOR EXPRESSION INHIBITION OF GENES KLF-1 AND BCL11A
EP2649182A4 (en)	2010-12-10	2015-05-06	Alnylam Pharmaceuticals Inc	Compositions and methods for increasing erythropoietin (epo) production
DK2670404T3 (en)	2011-02-02	2018-11-19	Univ Princeton	CIRCUIT MODULATORS AS VIRUS PRODUCTION MODULATORS
KR101697396B1 (ko)	2011-02-02	2017-01-17	엑스칼리아드 파마슈티컬즈, 인코포레이티드	결합 조직 성장 인자（ctgf）를 표적으로 하는 안티센스 화합물을 사용하여 켈로이드 또는 비후성 흉터를 치료하는 방법
CN103459598B (zh)	2011-02-03	2016-08-10	米尔纳医疗股份有限公司	Mir-124的合成模拟物
JP2014506791A (ja)	2011-02-03	2014-03-20	マーナセラピューティクスインコーポレイテッド	ｍｉＲ−３４の合成模倣体
US10017764B2 (en)	2011-02-08	2018-07-10	Ionis Pharmaceuticals, Inc.	Oligomeric compounds comprising bicyclic nucleotides and uses thereof
US9562853B2 (en)	2011-02-22	2017-02-07	Vanderbilt University	Nonaqueous backscattering interferometric methods
KR102365961B1 (ko)	2011-03-29	2022-02-23	알닐람 파마슈티칼스 인코포레이티드	Tmprss6 유전자의 발현을 억제하기 위한 조성물 및 방법
EP2694660B1 (en)	2011-04-03	2018-08-08	The General Hospital Corporation	Efficient protein expression in vivo using modified rna (mod-rna)
US20140186844A1 (en)	2011-04-26	2014-07-03	Swift Biosciences, Inc.	Polynucleotide primers and probes
WO2012151268A1 (en)	2011-05-02	2012-11-08	University Of Virginia Patent Foundation	Method and system for high throughput optical and label free detection of analytes
WO2012151289A2 (en)	2011-05-02	2012-11-08	University Of Virginia Patent Foundation	Method and system to detect aggregate formation on a substrate
EP2718439B1 (en)	2011-06-09	2017-08-09	CuRNA, Inc.	Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn
WO2012177949A2 (en)	2011-06-21	2012-12-27	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibition of expression of protein c (proc) genes
ES2923573T3 (es)	2011-06-21	2022-09-28	Alnylam Pharmaceuticals Inc	Composiciones de ARNi de proteína 3 de tipo angiopoyetina (ANGPTL3) y métodos de uso de las mismas
CN103649103A (zh)	2011-06-21	2014-03-19	阿尔尼拉姆医药品有限公司	用于抑制载脂蛋白c-iii(apoc3)基因表达的组合物与方法
EP3366312A1 (en)	2011-06-23	2018-08-29	Alnylam Pharmaceuticals, Inc.	Serpina 1 sirnas: compositions of matter and methods of treatment
JP2014526887A (ja)	2011-08-01	2014-10-09	アルナイラムファーマシューティカルズ，インコーポレイテッド	造血幹細胞移植の成功率を改善する方法
ES2651514T3 (es)	2011-08-11	2018-01-26	Ionis Pharmaceuticals, Inc.	Compuestos oligoméricos gapados que comprenden deoxirribonucleósidos modificados en 5 ' -en la brecha y usos de ellos
US9889209B2 (en)	2011-09-14	2018-02-13	Northwestern University	Nanoconjugates able to cross the blood-brain barrier
US9580713B2 (en)	2011-09-17	2017-02-28	Yale University	Fluoride-responsive riboswitches, fluoride transporters, and methods of use
CN103917556B (zh)	2011-10-14	2018-02-06	霍夫曼-拉罗奇有限公司	抗HtrA1抗体及使用方法
WO2013059740A1 (en)	2011-10-21	2013-04-25	Foundation Medicine, Inc.	Novel alk and ntrk1 fusion molecules and uses thereof
CN104114572A (zh)	2011-12-16	2014-10-22	现代治疗公司	经修饰的核苷、核苷酸和核酸组合物
CA2860731C (en)	2012-01-10	2023-02-28	M. Mahmood Hussain	Method of treating hyperlipidemia and atherosclerosis with mir-30c
SG11201405669XA (en)	2012-03-13	2014-10-30	Swift Biosciences Inc	Methods and compositions for size-controlled homopolymer tailing of substrate polynucleotides by a nucleic acid polymerase
US20150031750A1 (en)	2012-03-15	2015-01-29	The Scripps Research Institute	Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
US9610362B2 (en)	2012-03-16	2017-04-04	Valerion Therapeutics, Llc	Antisense conjugates for decreasing expression of DMPK
CA2868391A1 (en)	2012-04-02	2013-10-10	Stephane Bancel	Polynucleotides comprising n1-methyl-pseudouridine and methods for preparing the same
AU2013243948A1 (en)	2012-04-02	2014-10-30	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of proteins associated with human disease
US9133461B2 (en)	2012-04-10	2015-09-15	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the ALAS1 gene
WO2013159108A2 (en)	2012-04-20	2013-10-24	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising bicyclic nucleotides and uses thereof
US9127274B2 (en)	2012-04-26	2015-09-08	Alnylam Pharmaceuticals, Inc.	Serpinc1 iRNA compositions and methods of use thereof
US9273949B2 (en)	2012-05-11	2016-03-01	Vanderbilt University	Backscattering interferometric methods
US20140038182A1 (en)	2012-07-17	2014-02-06	Dna Logix, Inc.	Cooperative primers, probes, and applications thereof
WO2014045126A2 (en)	2012-09-18	2014-03-27	Uti Limited Partnership	Treatment of pain by inhibition of usp5 de-ubiquitinase
WO2014059353A2 (en)	2012-10-11	2014-04-17	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising bicyclic nucleosides and uses thereof
CA2887702C (en)	2012-10-26	2023-08-01	Geron Corporation	C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders
CA2890346A1 (en)	2012-11-05	2014-05-08	Foundation Medicine, Inc.	Novel fusion molecules and uses thereof
AU2013337277B2 (en)	2012-11-05	2018-03-08	Foundation Medicine, Inc.	Novel NTRK1 fusion molecules and uses thereof
WO2014081507A1 (en)	2012-11-26	2014-05-30	Moderna Therapeutics, Inc.	Terminally modified rna
EP2928303A4 (en)	2012-12-07	2016-07-13	Haplomics Inc	FACTOR VIII MUTATION REPAIR AND TOLERANCE INDUCTION
US20140200261A1 (en)	2013-01-17	2014-07-17	Moderna Therapeutics, Inc.	Signal-sensor polynucleotides for the alteration of cellular phenotypes
EP2945652B1 (en)	2013-01-18	2021-07-07	Foundation Medicine, Inc.	Methods of treating cholangiocarcinoma
WO2014130922A1 (en)	2013-02-25	2014-08-28	Trustees Of Boston University	Compositions and methods for treating fungal infections
CN105143470B (zh)	2013-02-28	2020-06-09	德克萨斯大学系统董事会	用于将癌症分类为易感于tmepai定向疗法以及治疗所述癌症的方法
EP2968391A1 (en)	2013-03-13	2016-01-20	Moderna Therapeutics, Inc.	Long-lived polynucleotide molecules
EP2971010B1 (en)	2013-03-14	2020-06-10	ModernaTX, Inc.	Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
CA3216595A1 (en)	2013-03-14	2014-10-02	Kevin Fitzgerald	Complement component c5 irna compositions and methods of use thereof
US8980864B2 (en)	2013-03-15	2015-03-17	Moderna Therapeutics, Inc.	Compositions and methods of altering cholesterol levels
JP2016522679A (ja)	2013-04-04	2016-08-04	プレジデントアンドフェローズオブハーバードカレッジ	ＣＲＩＳＰＲ／Ｃａｓ系を用いたゲノム編集の治療的使用
WO2014172698A1 (en)	2013-04-19	2014-10-23	Isis Pharmaceuticals, Inc.	Compositions and methods for modulation nucleic acids through nonsense mediated decay
TW201936624A (zh)	2013-05-22	2019-09-16	美商阿尼拉製藥公司	絲胺酸蛋白酶抑制因子Ａ１ｉＲＮＡ組成物及其使用方法
KR102486617B1 (ko)	2013-05-22	2023-01-12	알닐람 파마슈티칼스 인코포레이티드	Ｔｍｐｒｓｓ6 조성물 및 이의 사용 방법
WO2014197835A2 (en)	2013-06-06	2014-12-11	The General Hospital Corporation	Methods and compositions for the treatment of cancer
EP3007704B1 (en)	2013-06-13	2021-01-06	Antisense Therapeutics Ltd	Combination therapy for acromegaly
SMT202100691T1 (it)	2013-07-11	2022-01-10	Modernatx Inc	Composizioni 5 comprendenti polinucleotidi sintetici che codificano proteine correlate a crispr e sgrna sintetici e metodi d'uso
DK3041854T3 (da)	2013-08-08	2020-03-02	Scripps Research Inst	En fremgangsmåde til stedspecifik enzymatisk mærkning af nukleinsyrer in vitro gennem inkorporering af unaturlige nukleotider
US20160194625A1 (en)	2013-09-03	2016-07-07	Moderna Therapeutics, Inc.	Chimeric polynucleotides
US20160194368A1 (en)	2013-09-03	2016-07-07	Moderna Therapeutics, Inc.	Circular polynucleotides
US10077444B2 (en)	2013-10-02	2018-09-18	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the LECT2 gene
JP2016538829A (ja)	2013-10-03	2016-12-15	モデルナセラピューティクスインコーポレイテッドＭｏｄｅｒｎａＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	低密度リポタンパク質受容体をコードするポリヌクレオチド
TWI768330B (zh)	2013-10-04	2022-06-21	美國西奈山伊坎醫學院	抑制alas1基因表現的組合物及方法
EP3055426B1 (en)	2013-10-09	2019-06-19	The United States of America as represented by The Secretary Department of Health and Human Services	Detection of hepatitis delta virus (hdv) for the diagnosis and treatment of sjögren's syndrome and lymphoma
EP3502270B1 (en)	2013-10-21	2020-03-18	The General Hospital Corporation	Methods relating to circulating tumor cell clusters and the treatment of cancer
WO2015066708A1 (en)	2013-11-04	2015-05-07	Northwestern University	Quantification and spatio-temporal tracking of a target using a spherical nucleic acid (sna)
JP6527516B2 (ja)	2013-12-03	2019-06-05	ノースウェスタンユニバーシティ	リポソーム粒子、前述のものを作製する方法及びその使用
CA2844640A1 (en)	2013-12-06	2015-06-06	The University Of British Columbia	Method for treatment of castration-resistant prostate cancer
US10385388B2 (en)	2013-12-06	2019-08-20	Swift Biosciences, Inc.	Cleavable competitor polynucleotides
SG10201804960RA (en)	2013-12-12	2018-07-30	Alnylam Pharmaceuticals Inc	Complement component irna compositions and methods of use thereof
AU2014364520B2 (en)	2013-12-20	2020-01-02	The General Hospital Corporation	Methods and assays relating to circulating tumor cells
JP6736467B2 (ja)	2014-02-04	2020-08-05	ジェネンテック，インコーポレイテッド	平滑化変異体及びその使用方法
AU2015217301A1 (en)	2014-02-11	2016-08-25	Alnylam Pharmaceuticals, Inc.	Ketohexokinase (KHK) iRNA compositions and methods of use thereof
US10513706B2 (en)	2014-04-09	2019-12-24	The Scripps Research Institute	Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters
WO2015161170A2 (en)	2014-04-17	2015-10-22	Isis Pharmaceuticals, Inc.	Compositions and methods for modulation of smn2 splicing in a subject
TW201607559A (zh)	2014-05-12	2016-03-01	阿尼拉製藥公司	治療ｓｅｒｐｉｎｃ１相關疾患之方法和組成物
CA3215908A1 (en)	2014-05-22	2015-11-26	Alnylam Pharmaceuticals, Inc.	Angiotensinogen (agt) irna compositions and methods of use thereof
MX2016015569A (es)	2014-06-02	2017-04-25	Children´S Medical Center Corp	Metodos y composiciones para inmunomodulacion.
AU2015269412B2 (en)	2014-06-04	2020-03-12	Exicure Operating Company	Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
EP4039807A1 (en)	2014-06-10	2022-08-10	Erasmus University Rotterdam Medical Center	Antisense oligonucleotides useful in treatment of pompe disease
EP3169693B1 (en)	2014-07-16	2022-03-09	ModernaTX, Inc.	Chimeric polynucleotides
US9951327B1 (en)	2014-07-17	2018-04-24	Integrated Dna Technologies, Inc.	Efficient and rapid method for assembling and cloning double-stranded DNA fragments
WO2016014846A1 (en)	2014-07-23	2016-01-28	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of intrabodies
MX383117B (es)	2014-07-31	2025-03-13	Anji Pharmaceuticals Inc	Péptidos miméticos de la apoe y mayor potencia para depurar el colesterol en plasma.
WO2016028940A1 (en)	2014-08-19	2016-02-25	Northwestern University	Protein/oligonucleotide core-shell nanoparticle therapeutics
DK3185957T3 (da)	2014-08-29	2022-08-29	Alnylam Pharmaceuticals Inc	Patisiran til anvendelse ved behandlingen af transthyretin-medieret amyloidosis
ES2985036T3 (es)	2014-08-29	2024-11-04	Childrens Medical Ct Corp	Métodos y composiciones para el tratamiento del cáncer
WO2016033424A1 (en)	2014-08-29	2016-03-03	Genzyme Corporation	Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
EP3191591A1 (en)	2014-09-12	2017-07-19	Alnylam Pharmaceuticals, Inc.	Polynucleotide agents targeting complement component c5 and methods of use thereof
WO2016041058A1 (en)	2014-09-18	2016-03-24	The University Of British Columbia	Allele-specific therapy for huntington disease haplotypes
TWI864340B (zh)	2014-10-10	2024-12-01	美商艾爾妮蘭製藥公司	用於抑制hao1(羥酸氧化酶1(乙醇酸鹽氧化酶))基因表現的組合物及方法
WO2016061487A1 (en)	2014-10-17	2016-04-21	Alnylam Pharmaceuticals, Inc.	Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
EP3212794B1 (en)	2014-10-30	2021-04-07	Genzyme Corporation	Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
US20170312297A1 (en)	2014-11-10	2017-11-02	Glaxosmithkline Intellectual Property (No. 2) Limited	Long Acting Pharmaceutical Compositions For Hepatitis C
PE20170922A1 (es)	2014-11-10	2017-07-12	Glaxosmithkline Intellectual Property (No 2) Ltd	Composiciones de accion prolongada de combinacion y procedimientos para hepatitis c
TWI710633B (zh)	2014-11-10	2020-11-21	美商阿尼拉製藥公司	Ｂ型肝炎病毒（ＨＢＶ）ｉＲＮＡ組成物及其用途方法
HK1244843A1 (zh)	2014-11-17	2018-08-17	Alnylam Pharmaceuticals, Inc.	载脂蛋白c3(apoc3)irna组合物及其使用方法
KR20170078843A (ko)	2014-11-21	2017-07-07	노오쓰웨스턴 유니버시티	구형 핵산 나노입자 접합체의 서열 특이적 세포 흡수
US20160145547A1 (en)	2014-11-25	2016-05-26	Milliken & Company	Film-Encased Cleaning Composition
CA2970795A1 (en)	2014-12-18	2016-06-23	Alnylam Pharmaceuticals, Inc.	Reversir compounds
WO2016118812A1 (en)	2015-01-23	2016-07-28	Vanderbilt University	A robust interferometer and methods of using same
WO2016130806A2 (en)	2015-02-13	2016-08-18	Alnylam Pharmaceuticals, Inc.	Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
KR20260048600A (ko)	2015-03-27	2026-04-10	프레지던트 앤드 펠로우즈 오브 하바드 칼리지	변형된 t 세포 및 이의 제조 및 사용 방법
WO2016164746A1 (en)	2015-04-08	2016-10-13	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the lect2 gene
EP4365291A3 (en)	2015-06-12	2024-08-14	Alnylam Pharmaceuticals, Inc.	Complement component c5 irna compositions and methods of use thereof
WO2016205323A1 (en)	2015-06-18	2016-12-22	Alnylam Pharmaceuticals, Inc.	Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
WO2016209862A1 (en)	2015-06-23	2016-12-29	Alnylam Pharmaceuticals, Inc.	Glucokinase (gck) irna compositions and methods of use thereof
US10494632B2 (en)	2015-07-10	2019-12-03	Alnylam Pharmaceuticals, Inc.	Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof
EP3919619A1 (en)	2015-07-17	2021-12-08	Alnylam Pharmaceuticals, Inc.	Multi-targeted single entity conjugates
EP3332009A1 (en)	2015-08-04	2018-06-13	Yeda Research and Development Co., Ltd.	Methods of screening for riboswitches and attenuators
KR20250145703A (ko)	2015-09-02	2025-10-13	알닐람 파마슈티칼스 인코포레이티드	프로그램된 세포사 1 리간드 1 (PD-L1) iRNA 조성물 및 그의 사용 방법
KR102162324B1 (ko)	2015-10-30	2020-10-07	제넨테크, 인크.	항-HtrA1 항체 및 이의 사용 방법
AU2016349954B2 (en)	2015-11-05	2022-08-25	Antisense Therapeutics Ltd	Mobilizing leukemia cells
CA3007152A1 (en)	2015-12-07	2017-06-15	Erasmus University Medical Center Rotterdam	Enzymatic replacement therapy and antisense therapy for pompe disease
FI3386518T3 (fi)	2015-12-07	2025-09-25	Genzyme Corp	Menetelmiä ja koostumuksia serpinc1:een liittyvän häiriön hoitamiseksi
US11761007B2 (en)	2015-12-18	2023-09-19	The Scripps Research Institute	Production of unnatural nucleotides using a CRISPR/Cas9 system
US10627396B2 (en)	2016-01-29	2020-04-21	Vanderbilt University	Free-solution response function interferometry
JP2019509721A (ja)	2016-02-04	2019-04-11	キュリス，インコーポレイテッド	突然変異体スムースンド及びその使用方法
MA45295A (fr)	2016-04-19	2019-02-27	Alnylam Pharmaceuticals Inc	Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser
EP3469083A1 (en)	2016-06-10	2019-04-17	Alnylam Pharmaceuticals, Inc.	COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
HUE060123T2 (hu)	2016-06-24	2023-01-28	Scripps Research Inst	Új nukleozid-trifoszfát-transzporter és alkalmazásai
KR20190031306A (ko)	2016-07-21	2019-03-25	맥스시티 인코포레이티드	게놈 dna를 변경하기 위한 방법 및 조성물
NL2017295B1 (en)	2016-08-05	2018-02-14	Univ Erasmus Med Ct Rotterdam	Antisense oligomeric compound for Pompe disease
NL2017294B1 (en)	2016-08-05	2018-02-14	Univ Erasmus Med Ct Rotterdam	Natural cryptic exon removal by pairs of antisense oligonucleotides.
US11364304B2 (en)	2016-08-25	2022-06-21	Northwestern University	Crosslinked micellar spherical nucleic acids
TW202313978A (zh)	2016-11-23	2023-04-01	美商阿尼拉製藥公司	絲胺酸蛋白酶抑制因子Ａ１ｉＲＮＡ組成物及其使用方法
AU2017376950B2 (en)	2016-12-16	2024-02-22	Alnylam Pharmaceuticals, Inc.	Methods for treating or preventing TTR-associated diseases using transthyretin (TTR) iRNA compositions
IL314915B1 (en)	2017-01-23	2026-02-01	Regeneron Pharma	Variants of 17-beta-hydroxysteroid dehydrogenase and their uses
WO2018183969A1 (en)	2017-03-30	2018-10-04	California Institute Of Technology	Barcoded rapid assay platform for efficient analysis of candidate molecules and methods of making and using the platform
IL269927B2 (en)	2017-04-18	2025-04-01	Alnylam Pharmaceuticals Inc	Methods of treating patients with hepatitis B virus infection
UY37803A (es)	2017-07-10	2019-02-28	Genzyme Corp	Métodos y composiciones para tratar un evento de sangrado en un sujeto que padece hemofilia
MA49716A (fr)	2017-07-11	2021-04-07	Scripps Research Inst	Incorporation de nucléotides non naturels et procédés d'utilisationin vivo
AU2018300069C1 (en)	2017-07-11	2025-11-20	Synthorx, Inc.	Incorporation of unnatural nucleotides and methods thereof
JP2020526558A (ja)	2017-07-13	2020-08-31	ノースウェスタンユニバーシティ	オリゴヌクレオチド官能化金属有機構造体ナノ粒子を調製するための一般的かつ直接的な方法
AU2018301477A1 (en)	2017-07-13	2020-02-27	Alnylam Pharmaceuticals Inc.	Lactate dehydrogenase a (LDHA) iRNA compositions and methods of use thereof
WO2019028419A1 (en)	2017-08-03	2019-02-07	Synthorx, Inc.	CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES
WO2019055460A1 (en)	2017-09-13	2019-03-21	The Children's Medical Center Corporation	COMPOSITIONS AND METHODS FOR THE TREATMENT OF TRANSPOSON-ASSOCIATED DISEASES
KR20250046363A (ko)	2017-09-19	2025-04-02	알닐람 파마슈티칼스 인코포레이티드	트랜스타이레틴(ttr) 매개 아밀로이드증을 치료하기 위한 조성물 및 방법
AU2018360697A1 (en)	2017-11-01	2020-05-14	Alnylam Pharmaceuticals, Inc.	Complement component C3 iRNA compositions and methods of use thereof
US20200385719A1 (en)	2017-11-16	2020-12-10	Alnylam Pharmaceuticals, Inc.	Kisspeptin 1 (kiss1) irna compositions and methods of use thereof
WO2019100039A1 (en)	2017-11-20	2019-05-23	Alnylam Pharmaceuticals, Inc.	Serum amyloid p component (apcs) irna compositions and methods of use thereof
EP3714053B1 (en)	2017-11-22	2025-12-31	The University of Chicago	CHEMICALLY DEPENDENT PROBE EVALUATION OF PROTEIN ACTIVITY AND ITS USES
JP2021508491A (ja)	2017-12-18	2021-03-11	アルナイラムファーマシューティカルズ，インコーポレイテッドＡｌｎｙｌａｍＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	高移動度グループボックス−１（ＨＭＧＢ１）ｉＲＮＡ組成物及びその使用方法
KR102776907B1 (ko)	2017-12-29	2025-03-11	더 스크립스 리서치 인스티튜트	비천연 염기쌍 조성물 및 사용 방법
WO2019147743A1 (en)	2018-01-26	2019-08-01	Massachusetts Institute Of Technology	Structure-guided chemical modification of guide rna and its applications
CA3091857A1 (en)	2018-02-26	2019-08-29	Synthorx, Inc.	Il-15 conjugates and uses thereof
EP3775258A4 (en)	2018-03-28	2022-01-26	Board of Regents, The University of Texas System	IDENTIFICATION OF EPIGENETIC ALTERATIONS IN DNA ISOLATED FROM EXOSOMES
AU2019247490A1 (en)	2018-04-06	2020-10-22	Children's Medical Center Corporation	Compositions and methods for somatic cell reprogramming and modulating imprinting
WO2019217459A1 (en)	2018-05-07	2019-11-14	Alnylam Pharmaceuticals, Inc.	Extrahepatic delivery
TWI851574B (zh)	2018-05-14	2024-08-11	美商阿尼拉製藥公司	血管收縮素原（ＡＧＴ）ｉＲＮＡ組成物及其使用方法
CA3106701A1 (en)	2018-08-13	2020-02-20	Alnylam Pharmaceuticals, Inc.	Hepatitis b virus (hbv) dsrna agent compositions and methods of use thereof
US11987792B2 (en)	2018-08-16	2024-05-21	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the LECT2 gene
EP3849584A4 (en)	2018-09-14	2022-06-22	Northwestern University	PROGRAMMING PROTEIN POLYMERIZATION WITH DNA
CA3105385A1 (en)	2018-09-18	2020-03-26	Alnylam Pharmaceuticals, Inc.	Ketohexokinase (khk) irna compositions and methods of use thereof
CA3292164A1 (en)	2018-09-25	2025-11-29	Co Diagnostics Inc	Allele-specific design of cooperative primers for improved nucleic acid variant genotyping
WO2020069055A1 (en)	2018-09-28	2020-04-02	Alnylam Pharmaceuticals, Inc.	Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases
US10913951B2 (en)	2018-10-31	2021-02-09	University of Pittsburgh—of the Commonwealth System of Higher Education	Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
ES3059360T3 (en)	2018-11-08	2026-03-19	Synthorx Inc	Interleukin 10 conjugates and uses thereof
WO2020117706A1 (en)	2018-12-03	2020-06-11	Triplet Therapeutics, Inc.	Methods for the treatment of trinucleotide repeat expansion disorders associated with mlh3 activity
WO2020118259A1 (en)	2018-12-06	2020-06-11	Northwestern University	Protein crystal engineering through dna hybridization interactions
MY206794A (en)	2018-12-20	2025-01-08	Humabs Biomed Sa	Combination hbv therapy
US20220056455A1 (en)	2018-12-20	2022-02-24	Praxis Precision Medicines, Inc.	Compositions and methods for the treatment of kcnt1 related disorders
KR20210116509A (ko)	2019-01-16	2021-09-27	젠자임 코포레이션	Serpinc1 irna 조성물 및 그의 이용 방법
KR20260039812A (ko)	2019-02-06	2026-03-20	신톡스, 인크.	Il-2 콘쥬게이트 및 이의 사용 방법
EP3941483A4 (en)	2019-03-21	2023-10-18	Arnay Sciences, Llc	ANTISEN OLIGONUCLEOTIDES FOR ALLEL SPECIFICITY
SG11202112240VA (en)	2019-05-13	2021-12-30	Vir Biotechnology Inc	Compositions and methods for treating hepatitis b virus (hbv) infection
JP2022532652A (ja)	2019-05-17	2022-07-15	アルニラムファーマスーティカルズインコーポレイテッド	オリゴヌクレオチドの経口送達
CN120988042A (zh)	2019-06-14	2025-11-21	斯克利普斯研究所	用于在半合成生物体中复制、转录和翻译的试剂和方法
WO2021022108A2 (en)	2019-08-01	2021-02-04	Alnylam Pharmaceuticals, Inc.	CARBOXYPEPTIDASE B2 (CPB2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
EP4007812A1 (en)	2019-08-01	2022-06-08	Alnylam Pharmaceuticals, Inc.	Serpin family f member 2 (serpinf2) irna compositions and methods of use thereof
EP4013870A1 (en)	2019-08-13	2022-06-22	Alnylam Pharmaceuticals, Inc.	Small ribosomal protein subunit 25 (rps25) irna agent compositions and methods of use thereof
CN114555128A (zh)	2019-08-15	2022-05-27	新索思股份有限公司	采用il-2缀合物的免疫肿瘤学组合疗法
CN114555632A (zh)	2019-08-23	2022-05-27	新索思股份有限公司	Il-15缀合物及其用途
AU2020343255A1 (en)	2019-09-03	2022-03-24	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the LECT2 gene
MX2022002740A (es)	2019-09-10	2022-03-25	Synthorx Inc	Conjugados de il-2 y metodos de uso para tratar enfermedades autoinmunes.
US12319711B2 (en)	2019-09-20	2025-06-03	Northwestern University	Spherical nucleic acids with tailored and active protein coronae
EP4038189A1 (en)	2019-10-04	2022-08-10	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing ugt1a1 gene expression
WO2021076828A1 (en)	2019-10-18	2021-04-22	Alnylam Pharmaceuticals, Inc.	Solute carrier family member irna compositions and methods of use thereof
TW202134435A (zh)	2019-10-22	2021-09-16	美商阿尼拉製藥公司	補體成分ｃ３ｉｒｎａ組成物及其使用方法
US12378560B2 (en)	2019-10-29	2025-08-05	Northwestern University	Sequence multiplicity within spherical nucleic acids
CN119499394A (zh)	2019-11-01	2025-02-25	阿尔尼拉姆医药品有限公司	亨廷顿（HTT）iRNA药剂组合物及其使用方法
WO2021087325A1 (en)	2019-11-01	2021-05-06	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing dnajb1-prkaca fusion gene expression
IL291786A (en)	2019-11-04	2022-06-01	Synthorx Inc	Interleukin 10 conjugates and their use
CA3160329A1 (en)	2019-11-06	2021-05-14	Alnylam Pharmaceuticals, Inc.	Extrahepatic delivery
EP4055165A1 (en)	2019-11-06	2022-09-14	Alnylam Pharmaceuticals, Inc.	Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases
WO2021102373A1 (en)	2019-11-22	2021-05-27	Alnylam Pharmaceuticals, Inc.	Ataxin3 (atxn3) rnai agent compositions and methods of use thereof
EP4073251A1 (en)	2019-12-13	2022-10-19	Alnylam Pharmaceuticals, Inc.	Human chromosome 9 open reading frame 72 (c9orf72) irna agent compositions and methods of use thereof
TW202138559A (zh)	2019-12-16	2021-10-16	美商阿尼拉製藥公司	含類ＰＡＴＡＴＩＮ磷脂酶結構域３（ＰＮＰＬＡ３）ｉＲＮＡ組成物及其使用方法
US20230020092A1 (en)	2019-12-19	2023-01-19	Entrada Therapeutics, Inc.	Compositions for delivery of antisense compounds
WO2021154705A1 (en)	2020-01-27	2021-08-05	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Rab13 and net1 antisense oligonucleotides to treat metastatic cancer
WO2021154941A1 (en)	2020-01-31	2021-08-05	Alnylam Pharmaceuticals, Inc.	Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
MX2022009763A (es)	2020-02-10	2022-09-09	Alnylam Pharmaceuticals Inc	Composiciones y metodos para silenciar la expresion del factor de crecimiento endotelial vascular a (vegf-a).
KR20220143106A (ko)	2020-02-18	2022-10-24	알닐람 파마슈티칼스 인코포레이티드	아포지질단백질 C3 (APOC3) iRNA 조성물 및 이의 사용 방법
WO2021178607A1 (en)	2020-03-05	2021-09-10	Alnylam Pharmaceuticals, Inc.	Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases
BR112022017822A2 (pt)	2020-03-06	2022-11-08	Alnylam Pharmaceuticals Inc	Composições de irna de cetoexocinase (khk) e métodos de uso das mesmas
EP4121534A1 (en)	2020-03-18	2023-01-25	Alnylam Pharmaceuticals, Inc.	Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant
WO2021195307A1 (en)	2020-03-26	2021-09-30	Alnylam Pharmaceuticals, Inc.	Coronavirus irna compositions and methods of use thereof
EP4127171A2 (en)	2020-03-30	2023-02-08	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing dnajc15 gene expression
WO2021202902A1 (en)	2020-04-01	2021-10-07	Alnylam Pharmaceuticals, Inc.	ALPHA-2A ADRENERGIC RECEPTOR (ADRA2A) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
EP4133078A1 (en)	2020-04-06	2023-02-15	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing myoc expression
EP4133076A1 (en)	2020-04-07	2023-02-15	Alnylam Pharmaceuticals, Inc.	Angiotensin-converting enzyme 2 (ace2) irna compositions and methods of use thereof
WO2021206922A1 (en)	2020-04-07	2021-10-14	Alnylam Pharmaceuticals, Inc.	Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
CA3179678A1 (en)	2020-04-07	2021-10-14	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing scn9a expression
KR20230018377A (ko)	2020-04-27	2023-02-07	알닐람 파마슈티칼스 인코포레이티드	아포지질단백질 e (apoe) irna 제제 조성물 및 이의 사용 방법
MX2022013606A (es)	2020-04-30	2023-01-16	Alnylam Pharmaceuticals Inc	Composiciones de ácido ribonucleico interferente (arni) del factor b de complemento (cfb) y métodos de uso de las mismas.
WO2021231692A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of otoferlin (otof)
EP4150089A1 (en)	2020-05-15	2023-03-22	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of retinoschisin 1 (rs1)
WO2021231679A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
EP4150078A1 (en)	2020-05-15	2023-03-22	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
WO2021231673A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
WO2021231675A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
WO2021231685A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
WO2021231680A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
WO2021237097A1 (en)	2020-05-21	2021-11-25	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting marc1 gene expression
AR122534A1 (es)	2020-06-03	2022-09-21	Triplet Therapeutics Inc	Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3
JP2023530234A (ja)	2020-06-05	2023-07-14	ザ・ブロード・インスティテュート・インコーポレイテッド	新生物を治療するための組成物および方法
WO2021252557A1 (en)	2020-06-09	2021-12-16	Alnylam Pharmaceuticals, Inc.	Rnai compositions and methods of use thereof for delivery by inhalation
CN116075592A (zh)	2020-06-09	2023-05-05	阿尔尼拉姆医药品有限公司	用于沉默gpam(线粒体甘油-3-磷酸酰基转移酶1)表达的sirna组合物和方法
TW202214856A (zh)	2020-06-18	2022-04-16	美商阿尼拉製藥公司	黃嘌呤脫氫酶（ＸＤＨ）ｉＲＮＡ組成物及其使用之方法
CA3182458A1 (en)	2020-06-24	2021-12-30	Laura ROSEN	Engineered hepatitis b virus neutralizing antibodies and uses thereof
JP2023531509A (ja)	2020-06-25	2023-07-24	シンソークス，インコーポレイテッド	Ｉｌ－２コンジュゲートおよび抗ｅｇｆｒ抗体を用いる免疫腫瘍学併用療法
US20230257745A1 (en)	2020-07-10	2023-08-17	Alnylam Pharmaceuticals, Inc.	Circular siRNAs
EP4217489A1 (en)	2020-09-24	2023-08-02	Alnylam Pharmaceuticals, Inc.	Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
JP2023544413A (ja)	2020-10-05	2023-10-23	アルナイラムファーマシューティカルズ，インコーポレイテッド	Ｇタンパク質共役受容体７５（ＧＰＲ７５）ｉＲＮＡ組成物およびその使用方法
WO2022076859A1 (en)	2020-10-09	2022-04-14	Synthorx, Inc.	Immuno oncology therapies with il-2 conjugates
AU2021356693A1 (en)	2020-10-09	2023-06-15	Synthorx, Inc.	Immuno oncology combination therapy with il-2 conjugates and pembrolizumab
EP4232581A1 (en)	2020-10-21	2023-08-30	Alnylam Pharmaceuticals, Inc.	Methods and compositions for treating primary hyperoxaluria
AU2021364920A1 (en)	2020-10-23	2023-06-22	Sanofi	Reverse transcription of polynucleotides comprising unnatural nucleotides
EP4232582A1 (en)	2020-10-23	2023-08-30	Alnylam Pharmaceuticals, Inc.	Mucin 5b (muc5b) irna compositions and methods of use thereof
KR20230107625A (ko)	2020-11-13	2023-07-17	알닐람 파마슈티칼스 인코포레이티드	응고 인자 V(F5) iRNA 조성물 및 이의 사용 방법
WO2022119873A1 (en)	2020-12-01	2022-06-09	Alnylam Pharmaceuticals, Inc.	Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
WO2022125490A1 (en)	2020-12-08	2022-06-16	Alnylam Pharmaceuticals, Inc.	Coagulation factor x (f10) irna compositions and methods of use thereof
IL303886A (en)	2020-12-23	2023-08-01	Flagship Pioneering Inc	Compositions of modified trems and uses thereof
EP4271695A2 (en)	2020-12-31	2023-11-08	Alnylam Pharmaceuticals, Inc.	2'-modified nucleoside based oligonucleotide prodrugs
WO2022147214A2 (en)	2020-12-31	2022-07-07	Alnylam Pharmaceuticals, Inc.	Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
EP4274896A1 (en)	2021-01-05	2023-11-15	Alnylam Pharmaceuticals, Inc.	Complement component 9 (c9) irna compositions and methods of use thereof
WO2022174000A2 (en)	2021-02-12	2022-08-18	Alnylam Pharmaceuticals, Inc.	Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases
EP4291243A1 (en)	2021-02-12	2023-12-20	Synthorx, Inc.	Lung cancer combination therapy with il-2 conjugates and an anti-pd-1 antibody or antigen-binding fragment thereof
TW202245843A (zh)	2021-02-12	2022-12-01	美商欣爍克斯公司	Ｉｌ－２接合物及西米普利單抗（ｃｅｍｉｐｌｉｍａｂ）之皮膚癌組合療法
CN117222739A (zh)	2021-02-25	2023-12-12	阿尔尼拉姆医药品有限公司	朊病毒蛋白(prnp)irna组合物和其使用方法
TW202302847A (zh)	2021-02-26	2023-01-16	美商艾拉倫製藥股份有限公司	己酮糖激酶（ＫＨＫ）ｉＲＮＡ組成物及其使用方法
IL305442A (en)	2021-03-04	2023-10-01	Alnylam Pharmaceuticals Inc	Angiopoietin-like 3 (ANGPTL3) IRNA compositions and methods of using them
WO2022192038A1 (en)	2021-03-12	2022-09-15	Northwestern University	Antiviral vaccines using spherical nucleic acids
WO2022192519A1 (en)	2021-03-12	2022-09-15	Alnylam Pharmaceuticals, Inc.	Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof
WO2022212231A2 (en)	2021-03-29	2022-10-06	Alnylam Pharmaceuticals, Inc.	Huntingtin (htt) irna agent compositions and methods of use thereof
US20250243244A1 (en)	2021-03-31	2025-07-31	Entrada Therapeutics, Inc.	Cyclic cell penetrating peptides
EP4314293A1 (en)	2021-04-01	2024-02-07	Alnylam Pharmaceuticals, Inc.	Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof
MX2023012586A (es)	2021-04-26	2023-10-31	Alnylam Pharmaceuticals Inc	Composiciones de acido ribonucleico de interferencia (arni) de serina 6, proteasa transmembranaria (tmprss6) y sus metodos de uso.
JP2024519293A (ja)	2021-04-29	2024-05-10	アルナイラムファーマシューティカルズ，インコーポレイテッド	シグナル伝達兼転写活性化因子６（ＳＴＡＴ６）ｉＲＮＡ組成物およびその使用方法
WO2022235537A1 (en)	2021-05-03	2022-11-10	Alnylam Pharmaceuticals, Inc.	Compositions and methods for treating transthyretin (ttr) mediated amyloidosis
WO2022240721A1 (en)	2021-05-10	2022-11-17	Entrada Therapeutics, Inc.	Compositions and methods for modulating interferon regulatory factor-5 (irf-5) activity
US20240358845A1 (en)	2021-05-10	2024-10-31	Entrada Therapeutics, Inc.	Compositions and methods for intracellular therapeutics
WO2022240760A2 (en)	2021-05-10	2022-11-17	Entrada Therapeutics, Inc.	COMPOSITIONS AND METHODS FOR MODULATING mRNA SPLICING
WO2022245583A1 (en)	2021-05-18	2022-11-24	Alnylam Pharmaceuticals, Inc.	Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof
EP4341405A1 (en)	2021-05-20	2024-03-27	Korro Bio, Inc.	Methods and compositions for adar-mediated editing
WO2022256283A2 (en)	2021-06-01	2022-12-08	Korro Bio, Inc.	Methods for restoring protein function using adar
EP4347823A1 (en)	2021-06-02	2024-04-10	Alnylam Pharmaceuticals, Inc.	Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
EP4346904A1 (en)	2021-06-03	2024-04-10	Synthorx, Inc.	Head and neck cancer combination therapy comprising an il-2 conjugate and cetuximab
CN117561334A (zh)	2021-06-04	2024-02-13	阿尔尼拉姆医药品有限公司	人染色体9开放阅读框72（C9ORF72）iRNA药剂组合物和其使用方法
EP4351541A2 (en)	2021-06-08	2024-04-17	Alnylam Pharmaceuticals, Inc.	Compositions and methods for treating or preventing stargardt's disease and/or retinal binding protein 4 (rbp4)-associated disorders
PE20242357A1 (es)	2021-06-23	2024-12-16	Entrada Therapeutics Inc	Compuestos antisentido y metodos para dirigirse a repeticiones cug
WO2023278410A1 (en)	2021-06-29	2023-01-05	Korro Bio, Inc.	Methods and compositions for adar-mediated editing
US20230194709A9 (en)	2021-06-29	2023-06-22	Seagate Technology Llc	Range information detection using coherent pulse sets with selected waveform characteristics
WO2023283403A2 (en)	2021-07-09	2023-01-12	Alnylam Pharmaceuticals, Inc.	Bis-rnai compounds for cns delivery
WO2023003805A1 (en)	2021-07-19	2023-01-26	Alnylam Pharmaceuticals, Inc.	Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder
TW202421169A (zh)	2021-07-21	2024-06-01	美商艾拉倫製藥股份有限公司	代謝疾患相關的標靶基因ｉＲＮＡ組成物及其使用方法
CA3226878A1 (en)	2021-07-23	2023-01-26	Alnylam Pharmaceuticals, Inc.	Beta-catenin (ctnnb1) irna compositions and methods of use thereof
JP2024529437A (ja)	2021-07-29	2024-08-06	アルナイラムファーマシューティカルズ，インコーポレイテッド	３－ヒドロキシ－３－メチルグリタル－ＣＯＡレダクターゼ（ＨＭＧＣＲ）ｉＲＮＡ組成物およびその使用方法
CA3227852A1 (en)	2021-08-03	2023-02-09	Alnylam Pharmaceuticals, Inc.	Transthyretin (ttr) irna compositions and methods of use thereof
IL310295A (en)	2021-08-04	2024-03-01	Alnylam Pharmaceuticals Inc	iRNA compositions and methods for silencing angiotensinogen (AGT)
KR20240045300A (ko)	2021-08-13	2024-04-05	알닐람 파마슈티칼스 인코포레이티드	인자 XII (F12) iRNA 조성물 및 이의 사용 방법
WO2023034837A2 (en)	2021-08-31	2023-03-09	Alnylam Pharmaceuticals, Inc.	Cell death-inducing dffa-like effector b (cideb) irna compositions and methods of use thereof
WO2023034817A1 (en)	2021-09-01	2023-03-09	Entrada Therapeutics, Inc.	Compounds and methods for skipping exon 44 in duchenne muscular dystrophy
JP2024535850A (ja)	2021-09-17	2024-10-02	アルナイラムファーマシューティカルズ，インコーポレイテッド	補体成分（Ｃ３）をサイレンシングするためのｉＲＮＡ組成物および方法
AU2022345881A1 (en)	2021-09-20	2024-03-21	Alnylam Pharmaceuticals, Inc.	Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
KR20240067943A (ko)	2021-09-24	2024-05-17	알닐람 파마슈티칼스 인코포레이티드	미소관 연관 단백질 타우(MAPT) iRNA 제제 조성물 및 이의 사용 방법
MX2024004011A (es)	2021-10-01	2024-07-01	Adarx Pharmaceuticals Inc	Composiciones moduladoras de precalicreína y métodos de uso de estas.
MX2024004437A (es)	2021-10-15	2024-07-01	Alnylam Pharmaceuticals Inc	Composiciones de inhibidor de la angiotensina-receptor neprilisina (arni) de administracion extrahepatica y metodos de uso de las mismas.
US20250352667A1 (en)	2021-10-22	2025-11-20	Korro Bio, Inc.	Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
WO2023076450A2 (en)	2021-10-29	2023-05-04	Alnylam Pharmaceuticals, Inc.	HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
TW202333749A (zh)	2021-10-29	2023-09-01	美商艾拉倫製藥股份有限公司	補體因子ｂ（ｃｆｂ）ｉｒｎａ組成物及其使用方法
WO2023092060A1 (en)	2021-11-18	2023-05-25	Cornell University	Microrna-dependent mrna switches for tissue-specific mrna-based therapies
US20250302950A1 (en)	2021-12-20	2025-10-02	Synthorx, Inc.	Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
WO2023122750A1 (en)	2021-12-23	2023-06-29	Synthorx, Inc.	Cancer combination therapy with il-2 conjugates and cetuximab
WO2023141314A2 (en)	2022-01-24	2023-07-27	Alnylam Pharmaceuticals, Inc.	Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
EP4522742A2 (en)	2022-05-13	2025-03-19	Alnylam Pharmaceuticals, Inc.	Single-stranded loop oligonucleotides
WO2024006999A2 (en)	2022-06-30	2024-01-04	Alnylam Pharmaceuticals, Inc.	Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
JP2025527531A (ja)	2022-08-18	2025-08-22	アルナイラムファーマシューティカルズ，インコーポレイテッド	ユニバーサル非標的ｓｉｒｎａ組成物およびその使用方法
JP2025532593A (ja)	2022-09-15	2025-10-01	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	１７ｂ－ヒドロキシステロイドデヒドロゲナーゼ１３型（ｈｓｄ１７ｂ１３）ｉｒｎａ組成物およびその使用方法
JP2025532985A (ja)	2022-09-30	2025-10-03	アルナイラムファーマシューティカルズ，インコーポレイテッド	修飾二本鎖ｒｎａ剤
WO2024136899A1 (en)	2022-12-21	2024-06-27	Synthorx, Inc.	Cancer therapy with il-2 conjugates and chimeric antigen receptor therapies
EP4662311A2 (en)	2023-02-09	2025-12-17	Alnylam Pharmaceuticals, Inc.	Reversir molecules and methods of use thereof
EP4665865A1 (en)	2023-02-17	2025-12-24	Anjarium Biosciences AG	Methods of making dna molecules and compositions and uses thereof
TW202444349A (zh)	2023-03-20	2024-11-16	美商欣爍克斯公司	使用ｉｌ－２綴合物之癌症療法
AU2024254919A1 (en)	2023-04-12	2025-10-30	Alnylam Pharmaceuticals, Inc.	Extrahepatic delivery of double-stranded rna agents
WO2024220930A2 (en)	2023-04-20	2024-10-24	Adarx Pharmaceuticals, Inc.	Mapt-modulating compositions and methods of use thereof
WO2024220746A2 (en)	2023-04-21	2024-10-24	Flagship Pioneering Innovations Vii, Llc	Rnai agents targeting fatty acid synthase and related methods
WO2024226499A1 (en)	2023-04-24	2024-10-31	The Broad Institute, Inc.	Compositions and methods for modifying fertility
CN121398851A (zh)	2023-05-12	2026-01-23	阿达尔克斯制药有限公司	Nmda配体缀合的化合物及其用途
WO2024238385A2 (en)	2023-05-12	2024-11-21	Alnylam Pharmaceuticals, Inc.	Single-stranded loop oligonucleotides
IL324720A (en)	2023-05-26	2026-01-01	Adarx Pharmaceuticals Inc	SOD1 modulators and methods of using them
CN121712891A (zh)	2023-06-20	2026-03-20	阿达尔克斯制药有限公司	Lrrk2调节组合物及其使用方法
AU2024287308A1 (en)	2023-07-13	2025-12-18	Korro Bio, Inc.	Rna-editing oligonucleotides and uses thereof
AU2024299328A1 (en)	2023-07-21	2026-01-22	Marrow Therapeutics, Inc.	Hematopoietic cell targeting conjugates and related methods
KR20260049597A (ko)	2023-08-04	2026-04-14	알닐람 파마슈티칼스 인코포레이티드	Ctnnb1-관련 질환을 치료하기 위한 방법 및 조성물
WO2025072672A2 (en)	2023-09-27	2025-04-03	Judo Bio, Inc.	Slc6a19-targeting modulatory nucleic acid agents
WO2025072713A1 (en)	2023-09-27	2025-04-03	Judo Bio, Inc.	Polymyxins for delivery of agents to the kidney
WO2025072699A1 (en)	2023-09-27	2025-04-03	Judo Bio, Inc.	Aminoglycosides for delivery of agents to the kidney
WO2025076031A2 (en)	2023-10-03	2025-04-10	Alnylam Pharmaceuticals, Inc.	Peritoneal macrophages comprising a nanoparticle encapsulating a nucleic acid molecule and methods of use thereof
CN121909203A (zh)	2023-10-31	2026-04-21	科罗生物公司	包含氨基磷酸酯核苷酸间键的寡核苷酸
WO2025128799A1 (en)	2023-12-12	2025-06-19	Korro Bio, Inc.	Double-stranded rna-editing oligonucleotides and uses thereof
WO2025158385A1 (en)	2024-01-25	2025-07-31	Genzyme Corporation	Pegylated il-2 for suppressing adaptive immune response to gene therapy
US20250263702A1 (en)	2024-02-19	2025-08-21	Flagship Pioneering Innovations Vii, Llc	Rnai agents targeting cideb and related methods
TW202603166A (zh)	2024-03-20	2026-01-16	美商維泰克斯製藥公司	黏蛋白５Ｂ（ＭＵＣ５Ｂ）靶向ｓｉＲＮＡ及反義寡核苷酸及其使用方法
TW202603156A (zh)	2024-03-25	2026-01-16	美商欣爍克斯公司	用於生產多肽之合成tRNA合成酶及包含合成分子的細胞
WO2025217275A2 (en)	2024-04-10	2025-10-16	Flagship Pioneering Innovations Vii, Llc	Immune cell targeted compositions and related methods
WO2025259747A2 (en)	2024-06-12	2025-12-18	Alnylam Pharmaceuticals, Inc.	Dystrophy myotonic protein kinase (dmpk) irna compositions and methods of use thereof
WO2025259743A1 (en)	2024-06-12	2025-12-18	Alnylam Pharmaceuticals, Inc.	Dual conjugate compounds for extrahepatic delivery
WO2026006436A1 (en)	2024-06-25	2026-01-02	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of tar dna binding protein 43 kda (tdp43)
WO2026050243A1 (en)	2024-08-26	2026-03-05	Korro Bio, Inc.	Galnac conjugated oligonucleotides for rna editing
WO2026055461A1 (en)	2024-09-05	2026-03-12	Aperture Therapeutics, Inc.	Antibody oligonucleotide conjugates comprising an antisense polynucleotide agent conjugated to a cd33 antibody and methods of use thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0117578A2 (en) *	1983-02-23	1984-09-05	Shionogi & Co., Ltd.	Azole-substituted alcohol derivatives
EP0251086A2 (en) *	1986-06-23	1988-01-07	The Du Pont Merck Pharmaceutical Company	Antifungal carbinols
EP0298332A1 (de) *	1987-07-10	1989-01-11	Bayer Ag	Hydroxyalkyl-azolyl-Derivate
WO1989005581A1 (en) *	1987-12-17	1989-06-29	E.I. Du Pont De Nemours And Company	Antifungal carbinols
EP0405267A1 (de) *	1989-06-30	1991-01-02	Bayer Ag	Hydroxyethyl-cyclopropyl-azolyl-Derivate
WO1991012000A1 (en) *	1990-02-13	1991-08-22	E.I. Du Pont De Nemours And Company	ANILINE DERIVATIVES OF α-STYRYL CARBINOLS AS ANTIFUNGAL AGENTS

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1978953A (en) *	1928-10-17	1934-10-30	Du Pont	Method of preparing an alkali metal perborate
DE548432C (de) *	1928-10-17	1932-04-12	Degussa	Herstellung eines Perborates
US3327684A (en) *	1963-03-11	1967-06-27	Fairchild Camera Instr Co	Masking apparatus for spray coating
FR2226460B1 (tr) *	1973-04-20	1976-12-17	Interox
JPS5315717B2 (tr) *	1973-12-20	1978-05-26
DE2652776A1 (de) *	1975-05-13	1978-05-24	Interox Chemicals Ltd	Verfahren zur herstellung von natriumpercarbonat
LU72575A1 (tr) *	1975-05-23	1977-02-10
DE2712139C3 (de) *	1977-03-19	1982-05-19	Degussa Ag, 6000 Frankfurt	Natriumpercarbonat-Schichtpartikel
DE2651442C3 (de) *	1976-11-11	1979-11-15	Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt	Natriumpercarbonat-Partikel
DE2810379C3 (de) *	1978-03-10	1980-12-11	Degussa Ag, 6000 Frankfurt	Verfahren zur Herstellung von stabilisiertem Natriumpercarbonat
US4156039A (en) *	1976-11-11	1979-05-22	Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler	Sodium percarbonate particles (A)
LU76548A1 (tr) *	1977-01-10	1978-09-18
DE2800760C2 (de) *	1978-01-09	1983-01-27	Degussa Ag, 6000 Frankfurt	Verfahren zur Herstellung von Natriumpercarbonat aus einer Sodalösung bzw. -suspension
GB1575792A (en) *	1978-01-10	1980-10-01	Interox	Peroxygen compounds
CA1202854A (en) *	1982-06-10	1986-04-08	Muthumi Kuroda	Bleaching detergent composition
DE3321082C2 (de) *	1982-06-10	1996-08-22	Kao Corp	Bleich-Reinigungsmittel
DE3720277A1 (de) *	1987-06-19	1988-12-29	Degussa	Verfahren zur verminderung der neigung zum zusammenbacken von teilchenfoermigen aktivsauerstoffverbindungen
JP2636496B2 (ja) *	1990-11-21	1997-07-30	花王株式会社	安定な過炭酸ソーダ粒子及びその製造法

1993
- 1993-04-10 DE DE4311944A patent/DE4311944A1/de not_active Withdrawn
1994
- 1994-02-28 AU AU62078/94A patent/AU6207894A/en not_active Abandoned
- 1994-02-28 CZ CZ952498A patent/CZ249895A3/cs unknown
- 1994-02-28 PL PL94311035A patent/PL173925B1/pl unknown
- 1994-02-28 CN CN94191734A patent/CN1120832A/zh active Pending
- 1994-02-28 CA CA002159991A patent/CA2159991A1/en not_active Abandoned
- 1994-02-28 ES ES94909085T patent/ES2106515T3/es not_active Expired - Lifetime
- 1994-02-28 AT AT94909085T patent/ATE156096T1/de active
- 1994-02-28 KR KR1019950704418A patent/KR100308473B1/ko not_active Expired - Fee Related
- 1994-02-28 DE DE59403562T patent/DE59403562D1/de not_active Expired - Lifetime
- 1994-02-28 TW TW083101684A patent/TW265320B/zh active
- 1994-02-28 US US08/525,782 patent/US5658873A/en not_active Expired - Lifetime
- 1994-02-28 EP EP94909085A patent/EP0693039B1/de not_active Expired - Lifetime
- 1994-02-28 JP JP52265894A patent/JP3599737B2/ja not_active Expired - Fee Related
- 1994-02-28 FI FI954808A patent/FI954808L/fi unknown
- 1994-02-28 WO PCT/EP1994/000576 patent/WO1994024044A1/de not_active Ceased
- 1994-04-04 TR TR00294/94A patent/TR27402A/tr unknown
- 1994-04-07 SI SI9400166A patent/SI9400166A/sl unknown

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0117578A2 (en) *	1983-02-23	1984-09-05	Shionogi & Co., Ltd.	Azole-substituted alcohol derivatives
EP0251086A2 (en) *	1986-06-23	1988-01-07	The Du Pont Merck Pharmaceutical Company	Antifungal carbinols
EP0298332A1 (de) *	1987-07-10	1989-01-11	Bayer Ag	Hydroxyalkyl-azolyl-Derivate
WO1989005581A1 (en) *	1987-12-17	1989-06-29	E.I. Du Pont De Nemours And Company	Antifungal carbinols
EP0405267A1 (de) *	1989-06-30	1991-01-02	Bayer Ag	Hydroxyethyl-cyclopropyl-azolyl-Derivate
WO1991012000A1 (en) *	1990-02-13	1991-08-22	E.I. Du Pont De Nemours And Company	ANILINE DERIVATIVES OF α-STYRYL CARBINOLS AS ANTIFUNGAL AGENTS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
OGATA M. ET AL.: "Synthesis and oral antifungal activity of novel azolylpropanolones and related compounds", JOURNAL OF MEDICINAL CHEMISTRY, vol. 30, no. 6, June 1987 (1987-06-01), pages 1054 - 1068 *

Also Published As

Publication number	Publication date
FI954808A7 (fi)	1995-10-09
EP0693039B1 (de)	1997-07-30
PL311035A1 (en)	1996-01-22
JP3599737B2 (ja)	2004-12-08
DE59403562D1 (de)	1997-09-04
FI954808A0 (fi)	1995-10-09
ES2106515T3 (es)	1997-11-01
SI9400166A (en)	1994-12-31
FI954808L (fi)	1995-10-09
TW265320B (tr)	1995-12-11
US5658873A (en)	1997-08-19
DE4311944A1 (de)	1994-10-13
KR960701801A (ko)	1996-03-28
PL173925B1 (pl)	1998-05-29
CA2159991A1 (en)	1994-10-27
AU6207894A (en)	1994-11-08
ATE156096T1 (de)	1997-08-15
KR100308473B1 (ko)	2002-07-02
JPH08508707A (ja)	1996-09-17
WO1994024044A1 (de)	1994-10-27
CZ249895A3 (en)	1996-04-17
CN1120832A (zh)	1996-04-17
EP0693039A1 (de)	1996-01-24

Publication	Publication Date	Title
TR27402A (tr)	1995-02-28	Kaplanmis, sodyum perkarbonat tanecikleri, bunlari üretmeye mahsus bir yöntem ve bunlari ihtiva eden deterjan, temizleyici ve agartici terkipleri.
US4347149A (en)	1982-08-31	Aqueous bleach compositions
US4497725A (en)	1985-02-05	Aqueous bleach compositions
DE2965289D1 (en)	1983-06-01	Pourable scouring cleanser compositions
PL310951A1 (en)	1996-01-08	Stable, bifunctional phosphate-, metasilicate- and polymer-free low-alkaline cleaning agent tablets for machine dish-washing and method of making such tablets
GB1513305A (en)	1978-06-07	Bleaching compositions and method of bleaching
EP0813586B1 (en)	1999-07-28	Mold remover product
DK0746600T3 (da)	1999-01-04	Blegemiddel
JPH05500040A (ja)	1993-01-14	過酸化水素水の安定化
US2362401A (en)	1944-11-07	Detergent compositions
CA2029262A1 (en)	1991-05-10	Bleaching composition
AU668900B2 (en)	1996-05-23	Alkaline hydrogen peroxide composition
ATE16609T1 (de)	1985-12-15	Waessriges bleichmittel mit reinigungswirkung.
US5914305A (en)	1999-06-22	Peroxynitrite based bleaching systems
AU698072B2 (en)	1998-10-22	Lacto/peroxide bleaching solution, a bleaching system for forming the same and method of preparing and using the same
AU714835B2 (en)	2000-01-13	Cyanopyridine N-oxide peroxide bleach activators
EP0157483A1 (en)	1985-10-09	Peroxide activation
ES439370A1 (es)	1977-02-16	Un procedimiento para preparar perhidratos de tano-tetracar-boxilato.
MXPA97006869A (en)	1998-11-09	Removed product of m
ATE300600T1 (de)	2005-08-15	Bleichmittel enthaltende reinigungszusammensetzung
JPS565304A (en)	1981-01-20	Imidodisulfate peroxide, preparing the same, and detergent bleaching composition containing the same
TH19230A (th)	1996-06-21	สารผสมสารทำความสะอาดที่ใช้ฟอกจาง
TH16436B (th)	2004-03-17	สารผสมสารทำความสะอาดที่ใช้ฟอกจาง
TH2031A (th)	1984-12-03	ส่วนประกอบสารฟอกสีในการฟอกล้าง